Nurses Revision

nursesrevision@gmail.com

anatomy and physiology of the lymphatic system

Anatomy and Physiology of the Lymphatic System

Anatomy and Physiology of Lymphatic System

The lymphatic system is part of the circulatory system which begins with very small close ended vessels called lymphatic capillaries which is in contact with the surrounding tissues and interstitial fluid. The lymphatic system is almost a parallel system to the blood circulatory system.

It consists of:
  • Lymph
  • Lymph vessel
  • Lymph nodes
  • Diffuse lymphoid tissue
  • Bone marrow
Lymph

Lymph is a clear, watery fluid that circulates throughout the lymphatic system. It is essentially an ultrafiltrate of blood plasma that has left the capillaries and entered the interstitial spaces, eventually being collected by the lymphatic vessels. Understanding its origin and contents is key to grasping its physiological roles.

I. Definition of Lymph
  • A clear, yellowish or whitish fluid that flows through the lymphatic vessels.
  • It is derived from interstitial fluid (tissue fluid) that surrounds the cells, which in turn is formed from blood plasma that filters out of blood capillaries.
  • It is identical to interstitial fluid in its composition.
II. Composition of Lymph

The composition of lymph is very similar to blood plasma, but with some key differences, primarily a lower concentration of large proteins.

  1. Water: The primary component, providing the solvent for all other substances.
  2. Electrolytes: Ions such as sodium (Na+), potassium (K+), chloride (Cl-), bicarbonate (HCO3-), etc., are present in similar concentrations to plasma.
  3. Nutrients: Glucose, amino acids, fatty acids, and vitamins, which have filtered out of the blood capillaries and are essential for cellular metabolism.
  4. Metabolic Waste Products: Urea, creatinine, and other cellular waste products.
  5. Proteins:
    • Lower concentration than plasma: While most large plasma proteins are too big to easily exit blood capillaries, some do leak out into the interstitial fluid. Lymph serves to return these leaked proteins to the bloodstream.
    • Plasma proteins: Albumin, globulins (including antibodies), and clotting factors are present in smaller amounts.
  6. Cells:
    • Lymphocytes: These are the most abundant cells in lymph, especially after it has passed through lymph nodes. Lymphocytes are crucial for immune responses.
    • Macrophages: Phagocytic cells that engulf foreign particles, cellular debris, and pathogens.
    • Other immune cells: Neutrophils may be present, particularly during infection.
    • Erythrocytes (Red Blood Cells): Generally absent in lymph unless there is trauma or pathology.
  7. Fats (Chylomicrons): After a fatty meal, specialized lymphatic vessels in the small intestine (lacteals) absorb dietary fats, which are then transported as chylomicrons in the lymph (giving it a milky appearance, especially after a meal).
  8. Bacteria, Viruses, Cellular Debris, Damaged Tissues: These are also transported within the lymph to the lymph nodes for filtration and immune processing.
  9. Antibodies: Carried by lymphocytes and dissolved in the fluid component, providing immune protection.
III. Formation of Lymph

Lymph formation is a direct consequence of fluid exchange between blood capillaries and the interstitial spaces:

  1. Filtration at Capillary Ends: Due to the relatively high hydrostatic pressure within blood capillaries, a significant amount of fluid, along with dissolved substances (but not large proteins or blood cells), is forced out of the capillaries and into the interstitial spaces, becoming interstitial fluid.
  2. Absorption at Venule Ends: Most of this interstitial fluid (about 85-90%) is reabsorbed back into the capillaries at the venule end, where hydrostatic pressure is lower and osmotic pressure is higher.
  3. Lymphatic Drainage: However, about 10-15% of the interstitial fluid, along with any leaked plasma proteins and cellular debris, remains in the interstitial spaces. This fluid is collected by the blind-ended lymphatic capillaries, at which point it is officially called lymph. The unique structure of lymphatic capillaries allows large molecules to enter easily.
  4. Volume: Approximately 2-4 liters of lymph are formed and returned to the bloodstream each day. This represents about 1-3% of the body's total weight.
IV. Functions of Lymph

The composition of lymph directly supports its critical functions within the body:

  1. Fluid Balance:
    • Return of Excess Interstitial Fluid: Lymph collects excess fluid from the interstitial spaces and returns it to the bloodstream. This prevents edema (swelling) and maintains fluid homeostasis. Without this function, interstitial fluid would accumulate rapidly, leading to death within approximately 24 hours.
    • Transport of Proteins: It returns plasma proteins that have leaked out of blood capillaries into the interstitial fluid back to the circulation. This is crucial because if these proteins remained in the interstitial fluid, they would increase its osmotic pressure, drawing more fluid out of the capillaries and causing persistent edema.
  2. Immune Surveillance and Defense:
    • Transport of Pathogens to Lymph Nodes: Lymph effectively "sweeps up" bacteria, viruses, cellular debris, and foreign particles from tissues and transports them to regional lymph nodes.
    • Antigen Presentation: Within the lymph nodes, these pathogens and antigens are presented to lymphocytes (T and B cells) and macrophages, initiating specific immune responses.
    • Distribution of Immune Cells: Lymph circulates lymphocytes and antibodies throughout the body, providing a means for immune cells to patrol tissues and quickly respond to infections.
  3. Fat Absorption and Transport:
    • Transport of Dietary Lipids: In the small intestine, specialized lymphatic capillaries called lacteals absorb dietary fats (in the form of chylomicrons), cholesterol, and fat-soluble vitamins (A, D, E, K).
    • Bypassing Liver (Initially): This lymphatic pathway allows these absorbed fats to bypass initial processing by the liver and enter the systemic circulation directly via the thoracic duct.
Lymph Vessels (Lymphatics) and Lymph Capillaries

The lymphatic system begins with tiny, blind-ended capillaries that merge to form progressively larger vessels, eventually returning lymph to the bloodstream. These vessels have unique structural features that facilitate the collection and transport of lymph.

I. Lymph Capillaries
  1. Structure:
    • Blind-ended: Unlike blood capillaries which form a continuous loop, lymphatic capillaries originate as blind-ended tubules in the interstitial spaces. This "closed" end is crucial for initiating lymph flow.
    • Single Layer of Endothelial Cells: They are composed of a single layer of flattened endothelial cells, similar to blood capillaries.
    • No Basement Membrane: A key distinguishing feature is the absence or incomplete presence of a continuous basement membrane beneath the endothelial cells. This lack of structural support makes them more permeable.
    • Overlapping Endothelial Cells (Mini-Valves): The endothelial cells significantly overlap each other. These overlaps are loosely attached and form one-way flap-like mini-valves. When interstitial fluid pressure is high, these flaps open inwards, allowing fluid, proteins, bacteria, and larger particles to enter the capillary. When pressure inside the capillary is high, the flaps close, preventing lymph from leaking back into the interstitial space.
    • Anchoring Filaments: Fine collagen filaments (anchoring filaments) extend from the endothelial cells into the surrounding connective tissue. These filaments anchor the capillaries to the tissue, ensuring that when tissue fluid volume increases, the capillaries are pulled open, preventing collapse and facilitating fluid entry.
  2. Permeability:
    • Lymph capillaries are much more permeable than blood capillaries. This high permeability allows them to absorb not only excess interstitial fluid but also large molecules like plasma proteins (which have leaked out of blood capillaries), cell debris, bacteria, and even whole cancer cells. This ability to absorb large particles is vital for their immune and fluid balance functions.
  3. Distribution:
    • Lymph capillaries are extensive networks found almost everywhere blood capillaries are present. They permeate nearly all body tissues, forming dense plexuses within the interstitial spaces.
    • Exceptions: They are generally not found in certain areas, including:
      • Brain and Spinal Cord: The central nervous system has its own fluid drainage system (cerebrospinal fluid).
      • Bone Marrow: While lymphoid tissue is in bone marrow, it doesn't have lymphatic capillaries in the same way.
      • Avascular tissues: Like cartilage, epidermis of the skin, and the cornea of the eye.
      • Spleen: The spleen is a lymphoid organ, not a site of fluid collection from the interstitium via capillaries.
II. Lymph Vessels (Lymphatics)

Lymph capillaries merge to form progressively larger collecting vessels, which are collectively known as lymphatics. These vessels share structural similarities with veins but also have distinct features.

  1. Structure:
    • Similar to Veins, but Thinner Walls: Lymphatic vessels are structurally similar to veins, possessing three tunics (intima, media, externa), but their walls are generally much thinner and more delicate.
    • More Valves: A distinguishing feature of lymphatic vessels is the presence of an even greater number of valves than in veins. These numerous one-way valves are crucial for preventing the backflow of lymph and ensuring its unidirectional flow towards the heart. The presence of these valves gives the lymphatic vessels a characteristic beaded or segmented appearance.
    • Lymphangions: The segment of a lymphatic vessel between two consecutive valves is called a lymphangion. These lymphangions have smooth muscle in their walls, which contract rhythmically to propel lymph forward.
    • Afferent and Efferent Vessels: Lymphatic vessels entering a lymph node are called afferent lymphatic vessels, while those leaving a lymph node are efferent lymphatic vessels.
  2. Types of Lymphatic Vessels (in increasing size):
    • Lymphatic Capillaries: The starting point, blind-ended, highly permeable.
    • Collecting Lymphatic Vessels: Formed by the union of capillaries, these often travel alongside arteries and veins, having numerous valves.
    • Lymphatic Trunks: Formed by the convergence of collecting vessels. There are typically five major lymphatic trunks:
      • Lumbar trunks: Drain lymph from the lower limbs, pelvic organs, and anterior abdominal wall.
      • Bronchomediastinal trunks: Drain lymph from the thoracic viscera and chest wall.
      • Subclavian trunks: Drain lymph from the upper limbs.
      • Jugular trunks: Drain lymph from the head and neck.
      • Intestinal trunk (unpaired): Drains lymph from the digestive organs.
Lymphatic Ducts:

The two largest lymphatic vessels in the body, which ultimately return lymph to the venous circulation.

  • Thoracic Duct (Left Lymphatic Duct):
    • Origin: Begins in the abdomen as a dilated sac called the cisterna chyli (located anterior to the L1 and L2 vertebrae). The cisterna chyli receives lymph from the lumbar trunks and the intestinal trunk, meaning it drains the lower limbs, pelvic and abdominal organs.
    • Course: Ascends through the thoracic cavity, collecting lymph from the left broncho-mediastinal trunk, left subclavian trunk, and left jugular trunk.
    • Drainage Area: Drains lymph from the entire lower half of the body (both legs, pelvis, abdomen), the left side of the thorax, the left upper limb, and the left side of the head and neck.
    • Termination: Empties into the venous system at the junction of the left internal jugular vein and the left subclavian vein in the root of the neck.
  • Right Lymphatic Duct:
    • Origin: A much shorter vessel (about 1-2 cm long).
    • Drainage Area: Drains lymph from the right upper limb, the right side of the thorax, and the right side of the head and neck (from the right jugular, right subclavian, and right broncho-mediastinal trunks).
    • Termination: Empties into the venous system at the junction of the right internal jugular vein and the right subclavian vein in the root of the neck.
III. Overall Distribution

The lymphatic system is a vast, one-way network of vessels that transports lymph from peripheral tissues back to the cardiovascular system. It essentially runs parallel to the venous system, collecting fluid that cannot be reabsorbed by blood capillaries and filtering it before returning it to the blood.

Lymph Circulation

Lymph circulation is a one-way street, beginning in the peripheral tissues and ending back in the bloodstream. This accessory route is vital for maintaining fluid balance, transporting absorbed nutrients, and facilitating immune responses.

I. Path of Lymph Circulation
  1. Interstitial Fluid: Fluid (plasma minus large proteins) filters out of blood capillaries into the interstitial spaces, becoming interstitial fluid. This fluid surrounds tissue cells.
  2. Lymphatic Capillaries: The blind-ended, highly permeable lymphatic capillaries collect excess interstitial fluid, leaked proteins, cellular debris, and pathogens from the interstitial spaces. Once inside these capillaries, the fluid is called lymph.
  3. Collecting Lymphatic Vessels: Lymphatic capillaries merge to form larger collecting vessels. These vessels have numerous one-way valves, giving them a beaded appearance, and often travel alongside blood vessels.
  4. Lymph Nodes: Lymphatic vessels typically pass through one or more (often 8-10) lymph nodes. Lymph flows into a node via afferent lymphatic vessels, is filtered as it passes through the node, and then exits via efferent lymphatic vessels. This filtration process allows immune cells within the node to monitor the lymph for foreign substances.
  5. Lymphatic Trunks: Efferent vessels eventually converge to form larger lymphatic trunks. There are several major trunks throughout the body (e.g., lumbar, intestinal, broncho-mediastinal, subclavian, jugular).
  6. Lymphatic Ducts: The lymphatic trunks drain into one of two large lymphatic ducts:
    • Thoracic Duct:
      • Receives lymph from the cisterna chyli (which collects lymph from the lumbar trunks and intestinal trunk).
      • Also receives lymph from the left jugular, left subclavian, and left broncho-mediastinal trunks.
      • Drains: The entire lower body, left upper limb, left side of the thorax, and left side of the head and neck.
      • Terminates: Empties into the venous circulation at the junction of the left internal jugular vein and the left subclavian vein.
    • Right Lymphatic Duct:
      • Receives lymph from the right jugular, right subclavian, and right broncho-mediastinal trunks.
      • Drains: The right upper limb, right side of the thorax, and right side of the head and neck.
      • Terminates: Empties into the venous circulation at the junction of the right internal jugular vein and the right subclavian vein.
  7. Subclavian Veins: Once lymph enters the subclavian veins, it mixes with blood plasma and becomes part of the general venous circulation, eventually returning to the heart.
II. Factors Aiding Lymph Flow (The Lymphatic Pump)

Unlike the cardiovascular system, which has the heart as a central pump, the lymphatic system relies on extrinsic and intrinsic mechanisms to propel lymph against gravity and low pressure. These mechanisms collectively form what is sometimes called the "lymphatic pump."

  1. Skeletal Muscle Pump:
    • Mechanism: Contraction and relaxation of skeletal muscles surrounding lymphatic vessels compress the vessels. This compression pushes lymph forward through the one-way valves.
    • Importance: This is a major driving force, especially in the limbs. Increased physical activity (exercise) significantly enhances lymph flow by increasing muscle contractions. Conversely, prolonged inactivity leads to sluggish lymph flow.
  2. Respiratory Pump (Pressure Changes during Breathing):
    • Mechanism: During inhalation, the diaphragm descends, increasing intra-abdominal pressure and decreasing intrathoracic pressure. This pressure gradient compresses abdominal lymphatic vessels (including the cisterna chyli) and draws lymph into the thoracic duct, which is in the lower-pressure thoracic cavity. During exhalation, the reverse occurs, helping to maintain flow.
  3. Rhythmic Contraction of Smooth Muscle in Lymphatic Vessels (Intrinsic Lymphatic Pump):
    • Mechanism: The walls of larger lymphatic vessels (collecting vessels, trunks, ducts) contain smooth muscle cells, particularly in the segments between valves (lymphangions). These smooth muscles undergo slow, rhythmic, spontaneous contractions.
    • Importance: This intrinsic peristaltic-like action helps to actively propel lymph forward, especially when other external pumps are less active.
  4. Pulsations of Adjacent Arteries:
    • Mechanism: Lymphatic vessels often run in close proximity to arteries. The pulsations (throbbing) of these arteries, due to each heartbeat, can compress the lymphatic vessels and gently massage lymph along.
  5. One-Way Valves:
    • Mechanism: These numerous valves are crucial structural components within lymphatic vessels that ensure unidirectional flow. They prevent lymph from flowing backward due to gravity or pressure fluctuations.
  6. Compression of Tissues by External Objects:
    • Mechanism: External compression, such as massage, compression garments, or simply leaning on an object, can also temporarily increase pressure on lymphatic vessels and aid lymph flow.
  7. Hydrostatic Pressure in Interstitial Fluid:
    • Mechanism: The initial entry of interstitial fluid into lymphatic capillaries is driven by a pressure gradient. When interstitial fluid pressure is higher than the pressure inside the lymphatic capillary, the mini-valves open, allowing fluid to enter.
III. Significance of Lymph Circulation
  • Essential for Life: The continuous return of fluid and proteins from the interstitial spaces to the blood prevents fatal edema and hypovolemia (low blood volume).
  • Immune System Function: It allows immune cells and antigens to be circulated and processed in lymph nodes, initiating vital immune responses.
  • Nutrient Transport: Especially important for the absorption and transport of dietary fats.
Lymph Nodes

Lymph nodes are small, encapsulated organs that are strategically distributed throughout the body along the lymphatic vessels. They serve as primary sites for immune surveillance.

I. Structure of a Lymph Node

Lymph nodes are typically oval or bean-shaped, ranging in size from 1 mm to 25 mm (about 1 inch) in diameter.

  1. Capsule:
    • Each lymph node is enclosed by a dense fibrous capsule made of connective tissue.
    • Trabeculae: Extensions of the capsule, called trabeculae, extend inwards into the interior of the node, dividing it into compartments and providing structural support.
  2. Cortex and Medulla:
    • Cortex (Outer Region): The outer part of the lymph node. It contains:
      • Lymphoid Follicles (Nodules): Spherical clusters of lymphocytes.
      • Primary Follicles: Densely packed with small, inactive B lymphocytes.
      • Secondary Follicles: Develop in response to an antigen. They have a lighter-staining central area called a germinal center, which contains rapidly proliferating B cells, plasma cells (antibody-producing cells), and follicular dendritic cells.
      • Paracortex (Deep Cortex): The region between the follicles and the medulla. This area is rich in T lymphocytes and high endothelial venules (HEVs), through which lymphocytes can enter the node from the bloodstream. Dendritic cells, which present antigens to T cells, are also abundant here.
    • Medulla (Inner Region): The central part of the lymph node. It consists of:
      • Medullary Cords: Branching cords of lymphatic tissue that extend inward from the cortex. They contain B lymphocytes, plasma cells, and macrophages.
      • Medullary Sinuses: Large lymphatic capillaries that separate the medullary cords. Lymph flows through these sinuses.
  3. Lymphatic Sinuses (Channels for Lymph Flow):
    • These are a network of irregular channels lined by reticular cells and macrophages, forming a labyrinth through which lymph percolates.
    • Subcapsular Sinus (Marginal Sinus): Located immediately beneath the capsule, where afferent lymphatic vessels first empty.
    • Cortical Sinuses (Trabecular Sinuses): Extend from the subcapsular sinus, along the trabeculae.
    • Medullary Sinuses: Located in the medulla.
    • Flow Path: Lymph enters the subcapsular sinus, flows through cortical and medullary sinuses, and eventually collects in the efferent lymphatic vessels.
  4. Blood Supply:
    • Lymph nodes receive arterial blood and drain venous blood. High Endothelial Venules (HEVs) in the paracortex are particularly important, allowing lymphocytes to enter the node directly from the blood circulation.
  5. Afferent and Efferent Lymphatic Vessels:
    • Afferent Lymphatic Vessels: Several (typically 4-5) afferent vessels pierce the convex surface of the capsule, bringing lymph into the node. These vessels have valves that direct lymph inward.
    • Efferent Lymphatic Vessels: Fewer (typically 1-2) efferent vessels emerge from the hilum (the indented region) of the lymph node, carrying filtered lymph out of the node. These also have valves to prevent backflow.
II. Location and Distribution

Lymph nodes are found throughout the body, often clustered in strategic locations where they can effectively filter lymph from large regions. They are typically arranged in deep and superficial groups. Key large groups include:

  1. Cervical Lymph Nodes:
    • Location: In the neck, both superficial (along the sternocleidomastoid muscle) and deep (around the internal jugular vein).
    • Drainage: Head and neck.
    • Clinical Significance: Often swell during throat infections, colds, and ear infections.
  2. Axillary Lymph Nodes:
    • Location: In the armpits (axilla).
    • Drainage: Upper limbs, pectoral region, and the mammary glands.
    • Clinical Significance: Crucial in the staging of breast cancer, as cancer cells often metastasize via lymphatic drainage to these nodes.
  3. Inguinal Lymph Nodes:
    • Location: In the groin region.
    • Drainage: Lower limbs, external genitalia, and superficial abdominal wall.
    • Clinical Significance: May swell with infections or cancers of the lower extremities or pelvic area.
  4. Popliteal Lymph Nodes:
    • Location: Behind the knee.
    • Drainage: Superficial leg and foot.
  5. Thoracic Lymph Nodes:
    • Location: Within the mediastinum and around the hila of the lungs (hilar nodes), along the aorta (aortic nodes), and sternum (sternal nodes).
    • Drainage: Thoracic organs (lungs, heart, esophagus, mediastinum).
    • Clinical Significance: Involved in lung infections (e.g., tuberculosis) and lung cancer.
  6. Abdominal and Pelvic Lymph Nodes:
    • Location: Along the aorta (e.g., para-aortic nodes), iliac vessels, and within the mesentery of the intestines (e.g., mesenteric nodes).
    • Drainage: Abdominal and pelvic organs (e.g., gastrointestinal tract, kidneys, reproductive organs).
    • Clinical Significance: Involved in cancers of the digestive system and urogenital system.
  7. Cisterna Chyli: While not a true lymph node, this is a dilated sac that collects lymph from the lumbar and intestinal trunks, located in front of L1 & L2 vertebrae.
III. Functions of Lymph Nodes

Lymph nodes perform two primary, interconnected functions:

  1. Filtration of Lymph:
    • Mechanism: As lymph slowly flows through the intricate network of sinuses within the node, macrophages and reticular cells lining these sinuses phagocytose (engulf) debris, foreign particles, bacteria, viruses, dead cells, and cancer cells.
    • Importance: This cleansing action prevents harmful substances from reaching the bloodstream, effectively "purifying" the lymph before it is returned to the circulation. Lymph typically passes through around 8-10 nodes before returning to the blood, ensuring thorough filtration.
  2. Immune Surveillance and Activation:
    • Antigen Presentation: Lymph nodes are packed with lymphocytes (T cells and B cells) and antigen-presenting cells (APCs) like dendritic cells and macrophages. When pathogens or their antigens are carried into the node via lymph, APCs capture and present these antigens to lymphocytes.
    • Lymphocyte Proliferation: This antigen presentation triggers the activation and rapid proliferation (clonal expansion) of specific T and B lymphocytes that recognize the antigen.
    • Antibody Production: Activated B cells transform into plasma cells, which produce and secrete large quantities of antibodies into the lymph and eventually into the blood, targeting the invading pathogens.
    • Cell-Mediated Immunity: Activated T cells differentiate into various effector T cells (e.g., cytotoxic T cells that directly kill infected cells) and memory T cells.
    • Importance: Lymph nodes are the key sites where adaptive immune responses are initiated and amplified, leading to the eradication of infections and the development of immunological memory.
Lymphoid Tissues (e.g., tonsils, Peyer's patches)

Lymphoid tissue is a specialized connective tissue containing large numbers of lymphocytes and macrophages, forming the structural and functional basis of the immune system. It can be categorized into primary lymphoid organs (where lymphocytes mature) and secondary lymphoid organs/tissues (where lymphocytes become activated). For this objective, we'll focus on the more "diffuse" or "aggregated" lymphoid tissues.

I. Diffuse Lymphoid Tissue

This refers to collections of lymphocytes and macrophages that are loosely scattered within the connective tissue of mucous membranes, particularly those lining the gastrointestinal, respiratory, urinary, and reproductive tracts. It is the most common form of lymphoid tissue and lacks a distinct capsule. Its primary role is to protect these open passages from invading pathogens.

II. Aggregated Lymphoid Follicles (Nodules) - MALT

When lymphoid tissue is organized into dense, spherical clusters, it forms lymphoid follicles or nodules. These are typically unencapsulated. Many of these are part of Mucosa-Associated Lymphoid Tissue (MALT), which collectively guards the body's mucous membranes.

  1. Tonsils:
    • Description: Ring-like arrangements of lymphoid tissue located in the pharynx (throat) region, forming a protective circle at the entrance to the digestive and respiratory tracts. They are covered by epithelium that invaginates to form blind-ended crypts, which trap bacteria and particulate matter, allowing immune cells to destroy them.
    • Types:
      • Palatine Tonsils: Located at the posterior end of the oral cavity (the "tonsils" commonly removed). They are the largest and most often infected.
      • Lingual Tonsil: Located at the base of the tongue.
      • Pharyngeal Tonsil (Adenoids): Located on the posterior wall of the nasopharynx. When enlarged, they can obstruct breathing and are often referred to as "adenoids."
    • Significance: Act as the first line of defense against inhaled and ingested pathogens, initiating immune responses locally.
  2. Aggregated Lymphoid Follicles (Peyer's Patches):
    • Description: Large, oval or elongated clusters of lymphoid follicles found in the wall of the distal part of the small intestine (ileum). They are strategically positioned to monitor the bacterial flora of the gut and prevent the growth of pathogenic bacteria.
    • Significance: Crucial for immune surveillance in the intestine. They contain B cells that can differentiate into IgA-producing plasma cells, which secrete IgA antibodies into the gut lumen to neutralize pathogens. They also contain specialized M (microfold) cells that sample antigens from the gut lumen and present them to underlying immune cells.
  3. Appendix (Vermiform Appendix):
    • Description: A small, finger-like projection extending from the large intestine (cecum). Its wall contains a high concentration of lymphoid follicles.
    • Significance: Thought to be a lymphoid organ that plays a role in gut immunity, possibly serving as a "safe house" for beneficial gut bacteria or a site for immune cell maturation. Its exact functions are still being fully elucidated, but its lymphoid tissue indicates an immune role.
III. Other Locations of Lymphoid Tissue
  • Bone Marrow: Not just a site for hematopoiesis (blood cell formation), but also a primary lymphoid organ where B lymphocytes mature and where all lymphocytes originate.
  • Spleen: The largest lymphoid organ, it contains vast amounts of lymphoid tissue (white pulp) for filtering blood and initiating immune responses.
  • Thymus Gland: A primary lymphoid organ where T lymphocytes mature and are "educated."
  • Liver and Lungs: While not considered primary lymphoid organs, they contain significant populations of immune cells (e.g., Kupffer cells in the liver, alveolar macrophages in the lungs) and diffuse lymphoid tissue that contribute to local immunity.
IV. General Significance of Lymphoid Tissue
  • Pathogen Surveillance: They constantly monitor for pathogens entering through various portals of entry (e.g., respiratory, digestive).
  • Immune Response Initiation: They provide sites where lymphocytes can encounter antigens, proliferate, and differentiate into effector cells (e.g., plasma cells, cytotoxic T cells) to combat infections.
  • Immunological Memory: They contribute to the development of immunological memory, allowing for a faster and stronger response upon subsequent exposure to the same pathogen.
The Spleen

The spleen is a soft, blood-rich organ that is unique among lymphoid organs because it filters blood, not lymph. Its complex internal structure allows it to perform diverse immunological and hematological functions.

I. Anatomy and Location
  1. Location:
    • The spleen is located in the upper left quadrant of the abdominal cavity, nestled inferior to the diaphragm, posterior to the stomach, and superior to the left kidney.
    • It is typically between the 9th and 11th ribs. Its posterior surface is related to the diaphragm, and its medial surface to the stomach, left kidney, and tail of the pancreas.
    • It is intraperitoneal, meaning it is almost entirely surrounded by peritoneum.
  2. Size and Shape:
    • Typically about 12 cm (5 inches) long, 7 cm (3 inches) wide, and 3-4 cm (1.5 inches) thick. It weighs about 150-200 grams in adults.
    • It is oval-shaped, dark red-purple, and has a soft, friable (easily torn) consistency.
  3. Capsule and Trabeculae:
    • The spleen is enclosed by a thin, but relatively tough, fibrous capsule made of dense irregular connective tissue. This capsule also contains some smooth muscle cells, which can contract to help expel blood.
    • Trabeculae extend inward from the capsule, dividing the spleen into compartments and providing structural support. They also carry blood vessels into the splenic pulp.
  4. Hilum:
    • The medial surface of the spleen has an indentation called the hilum, where the splenic artery (bringing blood to the spleen) and splenic vein (draining blood from the spleen) enter and exit, respectively. Lymphatic vessels and nerves also pass through the hilum.
  5. Splenic Pulp:
    • The internal substance of the spleen is called the splenic pulp, which is highly vascularized and consists of two main components:
      • White Pulp:
        • Description: Consists of spherical clusters of lymphoid tissue, primarily lymphocytes (T and B cells) surrounding central arteries. It appears as "white" spots on a gross section.
        • Composition:
          • Periarteriolar Lymphoid Sheath (PALS): Concentric rings of T lymphocytes surrounding a central arteriole.
          • Splenic Follicles: Nodules of B lymphocytes, often with germinal centers, located within the PALS.
        • Function: Involved in immune responses. It is the site where immunological reactions to blood-borne antigens occur.
      • Red Pulp:
        • Description: Surrounds the white pulp and makes up the bulk of the spleen. It is rich in blood, giving it a deep red color.
        • Composition:
          • Splenic Cords (Cords of Billroth): Networks of reticular connective tissue containing macrophages, lymphocytes, plasma cells, and red blood cells.
          • Splenic Sinuses (Sinusoids): Wide, leaky capillaries that separate the splenic cords. These sinusoids have a discontinuous basement membrane, allowing blood cells to easily move between the cords and sinuses.
        • Function: Primarily involved in filtering blood, removing old/damaged red blood cells and platelets, and storing blood.
II. Key Functions of the Spleen
  1. Blood Filtration and Cleansing (Hematological Functions):
    • Removal of Old/Damaged Red Blood Cells: As red blood cells age (typically after 120 days), they become less flexible and are unable to navigate the narrow splenic sinusoids and cords. Macrophages in the red pulp recognize and phagocytose these senescent or damaged red blood cells, breaking down hemoglobin and recycling iron. This is often called the "graveyard of red blood cells."
    • Removal of Platelets: Similarly, old or damaged platelets are removed from circulation by macrophages in the spleen.
    • Removal of Other Blood-borne Debris: Phagocytic cells in the spleen also remove cellular debris, microorganisms, and other particulate matter from the blood.
  2. Immune Surveillance and Response (Immunological Functions):
    • Immune Response to Blood-borne Pathogens: The white pulp of the spleen is analogous to a very large lymph node, but it filters blood instead of lymph. It provides a site for lymphocytes (T and B cells) and antigen-presenting cells to encounter blood-borne antigens (e.g., bacteria, viruses) and initiate specific immune responses.
    • Antigen Presentation: Dendritic cells and macrophages in the white pulp present antigens to lymphocytes, leading to their activation.
    • Lymphocyte Proliferation: Activated B and T cells proliferate in the white pulp, generating an army of immune cells.
    • Antibody Production: Plasma cells generated in the spleen produce antibodies that are released into the bloodstream to target pathogens.
  3. Blood Storage:
    • Red Blood Cells and Platelets: The red pulp acts as a reservoir for blood. In some animals, the spleen can contract to release a significant volume of blood into circulation during hemorrhage or increased activity (though this function is less pronounced in humans). It also stores a considerable amount of platelets (up to 30-40% of the body's total platelet count).
    • Monocytes: The spleen serves as a large reservoir for monocytes, which can be rapidly deployed to sites of tissue injury or infection.
  4. Hematopoiesis (Fetal Life):
    • Fetal Blood Cell Production: During fetal development, the spleen is an important site of hematopoiesis (blood cell formation).
    • Adult Life (Pathological Conditions): In adults, the spleen generally does not produce red or white blood cells under normal conditions. However, in certain pathological conditions (e.g., severe anemia, myelofibrosis), it can resume its hematopoietic function (extramedullary hematopoiesis).
III. Clinical Significance
  • Splenomegaly: Enlargement of the spleen, often indicative of an underlying condition such as infection (e.g., mononucleosis), liver disease, or certain blood cancers.
  • Splenectomy: Surgical removal of the spleen. While individuals can live without a spleen, they become more susceptible to certain bacterial infections (particularly encapsulated bacteria like Streptococcus pneumoniae, Haemophilus influenzae type B, and Neisseria meningitidis) because the spleen is crucial for filtering these bacteria from the blood and initiating an early immune response.
Bone Marrow in the Lymphatic and Immune Systems

Bone marrow is a primary lymphoid organ, alongside the thymus, meaning it is where lymphocytes originate and mature. It is a highly vascular, soft, spongy tissue found in the medullary cavities of bones.

I. Anatomy and Location
  1. Location:
    • Found within the spongy (cancellous) bone and medullary cavities of long bones.
    • In adults, red bone marrow (the active, hematopoietic type) is primarily found in the flat bones (sternum, ribs, vertebrae, pelvic bones, skull) and the epiphyses (ends) of long bones (femur, humerus).
    • Yellow bone marrow (composed mostly of fat cells) replaces red marrow in the shafts of long bones during adolescence, though it can convert back to red marrow if needed (e.g., severe hemorrhage).
  2. Composition:
    • The primary cellular components are hematopoietic stem cells (HSCs), which are multipotent cells capable of differentiating into all types of blood cells, including immune cells.
    • It also contains stromal cells (fibroblasts, adipocytes, endothelial cells, macrophages) that create the microenvironment (bone marrow niche) necessary for hematopoiesis and lymphocyte development.
II. Key Roles in the Lymphatic and Immune Systems

Bone marrow performs two fundamental and indispensable roles:

  1. Site of Hematopoiesis (Origin of All Immune Cells):
    • All Lymphocytes and Other Leukocytes Originate Here: Hematopoietic stem cells (HSCs) in the red bone marrow are the progenitors for all blood cells, including:
      • Lymphoid Stem Cells: These differentiate into B lymphocytes, T lymphocytes (though T cells leave the bone marrow to mature in the thymus), and Natural Killer (NK) cells.
      • Myeloid Stem Cells: These differentiate into all other white blood cells (leukocytes) that are crucial for innate immunity (Neutrophils, Eosinophils, Basophils, Monocytes) and Erythrocytes/Platelets.
    • Continuous Production: The bone marrow continuously produces billions of new blood cells daily, ensuring a constant supply of immune cells to maintain the body's defense.
  2. Site of B Lymphocyte Maturation:
    • Primary Lymphoid Organ for B Cells: Unlike T cells, B lymphocytes undergo their entire maturation process (from lymphoid stem cell to immunocompetent, naive B cell) within the bone marrow.
    • Development and Selection: During this process, B cells acquire their unique B cell receptors (BCRs) and undergo rigorous selection to ensure that they are functional and, crucially, self-tolerant (i.e., do not react against the body's own tissues).
    • Release of Naive B Cells: Once mature, naive (antigen-inexperienced) B cells are released from the bone marrow into the bloodstream and lymphatic circulation, ready to encounter antigens in secondary lymphoid organs (like lymph nodes or the spleen).
  3. Site of Long-Lived Plasma Cells and Memory B Cells:
    • After an immune response, activated B cells can differentiate into long-lived plasma cells and memory B cells. A significant proportion of these long-lived cells migrate back to the bone marrow, where they reside for years or even decades.
    • Long-Lived Plasma Cells: Continuously produce antibodies, providing long-term humoral immunity.
    • Memory B Cells: Provide a rapid and robust secondary immune response upon re-exposure to the same antigen. The bone marrow acts as a crucial niche for the survival of these essential memory cells.
III. Clinical Significance
  • Bone Marrow Transplants: Used to treat various hematological disorders and cancers (e.g., leukemia, lymphoma) by replacing diseased or damaged bone marrow with healthy hematopoietic stem cells.
  • Immune Deficiencies: Dysfunction of the bone marrow can lead to severe immune deficiencies due to a lack of mature lymphocytes and other immune cells.
  • Autoimmune Diseases: Problems with B cell selection in the bone marrow can contribute to autoimmune diseases where B cells produce antibodies against self-antigens.
The Thymus Gland

The thymus is a primary lymphoid organ because it is the site of T-cell maturation and education. It is particularly active during childhood and adolescence, undergoing a process of involution (shrinkage) after puberty.

I. Structure and Location
  1. Location:
    • Located in the superior mediastinum, posterior to the sternum and anterior to the great vessels of the heart and the trachea.
    • It partially overlies the superior part of the heart and its great vessels.
  2. Size and Development:
    • It is relatively large in infants and children, continuing to grow until puberty.
    • After puberty, it begins to atrophy (shrink), a process called involution, where much of its lymphoid tissue is replaced by adipose (fat) tissue. While it becomes smaller, it remains functionally active throughout life, albeit at a reduced capacity.
  3. Gross Anatomy:
    • Typically bilobed (two lobes), connected by an isthmus.
    • Enclosed by a fibrous capsule.
    • The capsule sends trabeculae (septa) into the interior, dividing the lobes into numerous smaller compartments called lobules.
  4. Microscopic Anatomy (within each lobule): Each lobule has two distinct regions:
    • Cortex (Outer Region):
      • Composition: Densely packed with rapidly dividing T lymphocytes (thymocytes), macrophages, and specialized epithelial cells called thymic epithelial cells (TECs).
      • Function: This is the primary site for the initial stages of T-cell maturation and the first round of T-cell selection (positive selection).
    • Medulla (Inner Region):
      • Composition: Less densely packed with thymocytes. It contains more mature T cells, dendritic cells, macrophages, and characteristic structures called thymic (Hassall's) corpuscles.
      • Thymic Corpuscles: Concentric layers of flattened, keratinized epithelial cells. Their exact function is not fully understood, but they may be involved in the final stages of T-cell maturation and the production of specific cytokines.
      • Function: This is where the crucial second round of T-cell selection (negative selection) occurs, and where mature, naive T cells exit the thymus.
II. Key Functions of the Thymus Gland

The thymus's primary function is the education and maturation of T lymphocytes (T cells). This process ensures that T cells are both functional and self-tolerant.

  1. Site of T Lymphocyte Maturation:
    • "Boot Camp" for T Cells: T cell precursors (pro-thymocytes) originate in the bone marrow and migrate to the thymus. Here, they are called thymocytes.
    • Acquisition of T Cell Receptors (TCRs): Within the thymus, thymocytes undergo gene rearrangement to develop unique T cell receptors (TCRs) on their surface, which allow them to recognize specific antigens presented by other cells.
    • Immunocompetence: The process by which T cells become able to recognize and bind to antigens presented by MHC (Major Histocompatibility Complex) molecules.
  2. T-Cell Selection (Thymic Education):
    • This is a highly rigorous and critical process, often described as "survival of the fittest," ensuring that the body's T-cell repertoire is effective but not harmful. Over 95% of thymocytes die during this process.
    • Positive Selection (in Cortex):
      • Purpose: Ensures that T cells are capable of recognizing self-MHC molecules (MHC restriction).
      • Process: Thymocytes must successfully bind to MHC molecules presented by cortical thymic epithelial cells. T cells that bind too weakly or not at all undergo apoptosis (programmed cell death). This ensures the T cell will be able to interact with antigen-presenting cells later.
    • Negative Selection (in Medulla):
      • Purpose: Ensures that T cells do not react too strongly against self-antigens presented by self-MHC molecules (self-tolerance). This prevents autoimmune reactions.
      • Process: Thymocytes that bind too strongly to self-peptide-MHC complexes presented by medullary thymic epithelial cells or dendritic cells undergo apoptosis. This eliminates potentially autoreactive T cells.
      • AIRE (Autoimmune Regulator) Gene: Medullary TECs express the AIRE gene, which allows them to present a wide array of "self" proteins from other parts of the body, thus educating T cells about self-antigens they might encounter elsewhere.
  3. Hormone Production:
    • Thymic epithelial cells produce several hormones, such as thymosin, thymopoietin, and thymulin, which are essential for the maturation and differentiation of T cells within the thymus.
  4. Release of Naive T Cells:
    • Only about 2-5% of the original thymocytes successfully pass both positive and negative selection. These "survivors" are mature, immunocompetent, and self-tolerant naive T cells.
    • These mature T cells exit the thymus and populate secondary lymphoid organs (like lymph nodes and spleen), ready to encounter their specific antigens and participate in immune responses.
III. Clinical Significance
  • DiGeorge Syndrome: A congenital disorder where the thymus fails to develop, leading to a severe deficiency of T cells and profound immunodeficiency, making individuals highly susceptible to infections.
  • Thymoma: A tumor of the thymic epithelial cells. It can sometimes be associated with autoimmune diseases like myasthenia gravis.
  • Involution: While it shrinks, the thymus remains functionally important throughout life, continually supplying T cells, though at a reduced rate. Loss of thymic function early in life (e.g., due to disease or surgical removal) can significantly compromise the immune system.

Anatomy and Physiology of the Lymphatic System Read More »

benign prostatic hyperplasia bph

Benign Prostatic Hyperplasia (BPH)

BPH 

BPH-Benign prostatic hyperplasia is the enlargement, or hypertrophy, of the prostate gland.

 BPH is common in elderly men over 60 years and above

Common causes of BPH and Pathophysiology

The outcome of BPH depends on two major factors i.e.

  1. Anatomical factors:   These involve enlargement of the Prostate gland which produces a physical blockage at the neck of the bladder against urinary flow.  This results in increased responsiveness of the prostate gland to androgens and estrogens. 
  2.  Dynamic factors; These result from excessive sympathetic stimulation via alpha-1 receptors in the prostate gland leading to increased tone at the sphincters of urinary bladder and the prostate.

The pathophysiology of BPH is as follows:

  • Resistance. BPH is a result of complex interactions involving resistance in the prostatic urethra to mechanical and spastic effects.
  • Obstruction. The hypertrophied lobes of the prostate may obstruct the bladder neck or urethra, causing incomplete emptying of the bladder and urinary retention.
  • Dilation. Gradual dilation of the ureters and kidneys can occur.

Resulting symptoms of BPH.

  • Urinary frequency. Frequent trips to the bathroom to urinate may be an early sign of a developing BPH.
  • Urinary urgency. This is the sudden and immediate urge to urinate.
  • Nocturia. Urinating frequently at night is called nocturia.
  • Weak urinary stream. Decreased and intermittent force of stream is a sign of BPH.
  • Dribbling urine. Urine dribbles out after urination.
  • Straining. There is presence of abdominal straining upon urination.
  • Urinary retention
  • Decrease in force of urinary out put
  • Intermittency during urination

Investigations and Diagnosis of BPH

  • Digital rectal examination (DRE). A DRE often reveals a large, rubbery, and nontender prostate gland.

bph dre

  • Urinalysis. A urinalysis to screen for hematuria and UTI is recommended.
  • Prostate specific antigen levels. A PSA level is obtained if the patient has at least a 10-year life expectancy and for whom knowledge of the presence of prostate cancer would change management.
  • Urinalysis: Color: Yellow, dark brown, dark or bright red (bloody); appearance may be cloudy. pH 7 or greater (suggests infection); bacteria, WBCs, RBCs may be present microscopically.
  • Urine culture: May reveal Staphylococcus aureus, Proteus, Klebsiella, Pseudomonas, or Escherichia coli.
  • Urine cytology: To rule out bladder cancer.
  • BUN/Cr: Elevated if renal function is compromised.
  • Prostate-specific antigen (PSA): Glycoprotein contained in the cytoplasm of prostatic epithelial cells, detected in the blood of adult men. Level is greatly increased in prostatic cancer but can also be elevated in BPH. Note: Research suggests elevated PSA levels with a low percentage of free PSA are more likely associated with prostate cancer than with a benign prostate condition.
  • WBC: May be more than 11,000/mm3, indicating infection if patient is not immunosuppressed.
  • Uroflowmetry: Assesses degree of bladder obstruction.
  • IVP with post voiding film: Shows delayed emptying of bladder, varying degrees of urinary tract obstruction, and presence of prostatic enlargement, bladder diverticula, and abnormal thickening of bladder muscle.
  • Voiding cystourethrography: May be used instead of IVP to visualize bladder and urethra because it uses local dyes.
  • Cystometrogram: Measures pressure and volume in the bladder to identify bladder dysfunction unrelated to BPH.
  • Cystourethroscopy: To view degree of prostatic enlargement and bladder-wall changes (bladder diverticulum).
  • Cystometry: Evaluates detrusor muscle function and tone.
  • Transrectal prostatic ultrasound: Measures size of prostate and amount of residual urine; locates lesions unrelated to BPH.

Classification of drugs for BPH

They are classified into 3 major groups;

  1. 5 alpha-reductase inhibitors
  2. Alpha-1 selective blockers
  3. Combined therapies

5 alpha-reductase inhibitors  

They inhibit an enzyme 5 alpha – reductase in the prostate thus preventing the conversion of testosterone into active form thus suppressing the activity of androgens in the prostate. The overall effect is decreased growth of the prostate gland.

N.B the effects of these drugs is not prompt and don’t relieve urine retention.

  • Finasteride 5mg o.d.
  • Dutasteride 0.5mg o.d

Both are administered orally

Alpha – 1 selective blockers

They block alpha I receptors in the prostate and bladder leading to relaxation of sphincter and so improved urine flows.

These are grouped into two;

  • Short acting agent e.g. Prazosin, Indamine, and Alfuzosin.
  • Long acting agents e.g. Tamucurosin, Doxazocin and Terazosin.

Doses;

  • Prazosin 0.5-1mg o.d given at bed time after few days orally then maintained  at 1mg b.d * 3/7
  • Terazosin 2-10mg o.d
  • Doxazocin  1mg o.d.
  • Tamucurosin 0.4 mg once daily given with meals orally.

 NB:  Tamucurocin is a long acting member best indicated since doesn’t interfere with blood pressure

Trazocin should be given at a lower dose then maintained later this is to avoid hypotension while standing

Their effects are faster thus usually combined with Finasteride

Adverse effects:

  • Postural hypotension
  • Tachycardia reflex

Others rarely used members include; Phentolamine and phenoxybenzamine

Medical Management

The goals of medical management of BPH are to improve the quality of life and treatment depends on the severity of symptoms.

  • Catheterization. If a patient is admitted on an emergency basis because he is unable to void, he is immediately catheterized.
  • Cystostomy. An incision into the bladder may be needed to provide urinary drainage.

Pharmacologic Management

  • Alpha-adrenergic blockers (eg, alfuzosin, terazosin), which relax the smooth muscle of the bladder neck and prostate, and 5alpha reductase inhibitors.
  • Hormonal manipulation with antiandrogen agents (finasteride [Proscar]) decreases the size of the prostate and prevents the conversion of testosterone to dihydrotestosterone (DHT).
  • Use of phytotherapeutic agents and other dietary supplements (Serenoa repens [saw palmetto berry] and Pygeum africanum [African plum]) are not recommended, although they are commonly used.
  • One herbal medication effective against BPH is Saw Palmetto.
Saw Palmetto bph
Saw Palmetto

Surgical Management

Other treatment options include minimally invasive procedures and resection of the prostate gland.

  • Transurethral microwave heat treatment. This therapy involves the application of heat to prostatic tissue.
  • Transurethral needle ablation (TUNA). TUNA uses low-level radio frequencies delivered by thin needles placed in the prostate gland to produce localized heat that destroys prostate tissue while sparing other tissues.
  • Transurethral resection of the prostate (TURP). TURP involves the surgical removal of the inner portion of the prostate through an endoscope inserted through the urethra.
  • Open prostatectomy. Open prostatectomy involves the surgical removal of the inner portion of the prostate via a suprapubic, retropubic, or perineal approach for large prostate glands.

Benign Prostatic Hyperplasia (BPH) Read More »

Erectile dysfunction medications

Erectile Dysfunction Medications

Erectile Dysfunction

Erectile dysfunction, ED is the inability of the male to attain and maintain an erection sufficient to permit satisfactory sexual intercourse.

Penile erectile dysfunction is a condition in which the corpus cavernosum does not fill with blood to allow for penile erection. This can result from the aging process and in vascular and neurological conditions.

So, what is impotence?

Impotence, a term often used synonymously with ED, many involve a total inability to achieve erection, an inconsistent ability to achieve or ability to sustain only brief erections.

Physiology of an Erection

This begins with stimulus such as sight and touch. This stimulates the parasympathetic nervous division that transmits nerve impulses to the erectile tissue of the penis (corpus carvernosum). The nerve endings release nitric oxide(NO) which binds on muscle cells in the penis leading to generation of cyclic GMP (Cyclic Guanosine monophosphate) which relaxes the muscle cells in the corpus cavernosum leading to creation of larger intracellular spaces and sinusoids. More blood flows into the erectile tissues, the tissue expands compresses the veins leaving the penis, thus increased blood volume in the organ and one erects.

      Erection is continuously maintained during sexual intercourse by the release of NO, and prostaglandin E1 (PGE1).

Termination of erection( Detumescence ) is brought about by 2 events i.e.

  • Activity of enzyme phosphodiesterase type 5 enzyme (PDE-5) which catalyzes the breakdown of GMP into inactive form.
  • Stimulation of sympathetic nervous division to bring about the contraction of the penile muscles terminating ejaculation.

 

Pharmacology application of the above;

  • Erection relies on the penile blood flow thus an event that interferes with penile blood flow results into penile dysfunction.
  • Any factor which interferes with neuro-transmitters such as acetylcholine may end with Erectile Dysfunction.
  • Psychological factors e.g. stress may as well interfere initiation of erection.

Classification of Erectile Dysfunction.

Primary Erectile Dysfunction; is where a man has never  been able to attain and maintain an erection for sexual intercourse

Secondary Erectile Dysfunction: is where impotence occurs in a man who has past history of satisfactory sexual performance.

Causes of Erectile Dysfunction

  • Erectile Dysfunction mainly occurs past middle age and is common after the age of 65 years.

A variety of vascular, Neurological, hormonal or endocrinal, pharmacological or psychological and genetic causes may underly the disorder, i.e.

  • Vascular diseases: Blood supply to the penis can become blocked or narrowed as a result of vascular disease such as atherosclerosis (hardening of the arteries).
  • Neurological disorders (such as multiple sclerosis): Nerves that send impulses to the penis can become damaged from stroke, diabetes, or other causes.
  • Psychological states: These include stress, depression, lack of stimulus from the brain and performance anxiety.
  • Trauma: An injury could contribute to symptoms of Erectile Dysfunction.
  • Cancer treatments;  near the pelvis can affect the penis’ functionality.
    Surgery and or radiation for cancers in the lower abdomen or pelvis can cause Erectile dysfunction. Treating prostate, colon-rectal or bladder cancer often leaves men with Erectile dysfunction.
  • Drugs;  used to treat other health problems can negatively impact erections such as Cimetidine (Tagamet), Ranitidine (Zantac)

Classification of Drugs used to treat Erectile Dysfunction.

There are divided into 4 groups;

  • Central inhibitors
  • Peripheral inhibitors
  • Central conditioners
  • Peripheral conditioners

PDE 5 Inhibitors/Peripheral Inhibitors.

These are agents which act in the penile tissue to maintain the environment of erection. They include phosphodiesterase-5 inhibitors e.g. sildenafil, tadalafil, and vardenafil are selective PDE-5 inhibitors developed drugs in the past decade and found effective in a majority of patients with Erectile Dysfunction.

SILDENAFIL:

 It is an orally active drug

Classification:

Therapeutic– ED agent, vasodilator

Pharmacological– phosphodiesterase type 5 inhibitor

Brand names:
  • Kamagra
  • Penegra
  • viagra
  • Caverta
  • Edegra 25, 50, 100mg tablets
Indications:         
  • Erectile Dysfunction
  • Pulmonary Hypertension.
Mechanism of action;

 Sildenafil acts by selectively inhibiting an enzyme phosphodiesterase-5 and enhancing nitric oxide action in corpus cavernosum thus preventing the breakdown of GMP produces smooth muscle relaxation of the corpus cavernosum which in turn promotes increased blood flow and subsequent erection hence sex intercourse and exercise tolerance is improved but it has no effect on penile (swelling) tumescence in the absence of sexual activity. It doesn’t cause priapism in most patient.

 Dosage:

  It is recommended in the dose of

  • 50mg for men less than 65 years,
  • elderly 25mg if not effective then 100mg 1 hour by intercourse.

Duration and degree of penile erection is increased in 74-82% of men with Erectile Dysfunction including diabetic Neuropathy cases.

However, Sildenafil is effective in men who have lost libido or when ED is due to spinal cord injury or damaged Nervic eregantis since Nitric Oxide is an important regulator of pulmonary vascular resistance, PDE-5 inhibitor lower pulmonary circulation than vardenafil and is only PDE-5 inhibitor shown to improve arterial   oxygenation in pulmonary Hypertension. It has now become the drug of choice for this condition

N.B.; it should be given once a day.  

Adverse effects/ side effects:

These are mainly due to preservation of nitric oxide which causes vasodilatation in the brain.

  • Dizziness and headache
  • Nasal congestion
  • Hypotension and palpitation
  • Loose emotion
  • A feeling of dependency/ addiction
  • Flushing
  • Tachycardia
  • Muscle pain
  • Diarrhoea
  • Sildenafil in addiction, weakly inhibits the isoenzyme PDE-5 which is involved in photoreceptor transduction in the retina. As such impairment of colour vision especially, blue-green discrimination occurs in some recipients.
  • Hormones and related drug neuropathy among users of PDE-5 inhibitors have be reported.
Contraindications:
  • In patients with coronary heart diseases.
  • Those taking nitrates. Though sildenafil remains effective for less than 2hours, it is advised that nitrates should be avoided for 24hours
  • Presence of liver or kidney disorder
  • Peptic ulcer, bleeding disorder
  • Patients of leukemia, sickle cell anemia, myocardial infarction etc.
Drug interactions:
  •  Sildenafil markedly potentiates the vasodilator action of nitrates, precipitates fall in Blood Pressure and myocardial infarction may occur.
  • Inhibitors of CYP3A4 like erythromycin, Ketoconazote, cemetidine may potentiate its action i.e. may increase Sildenafil plasma concentration.
  • Vitamin k antagonist may increase the risk of bleeding.
  • Concomitant use with alpha- blockers may lead to hypotension.

N.B: men even without Erectile Dysfunction are going for it to enhance sexual satisfaction.

Nursing implications:
  • Determine Erectile Dysfunction before administration.
  • Monitor hemodynamic parameters and exercise before and after therapy
Patient/ family teaching:
  • Instruct the patient to take drugs at least 1 hour before sexual activity
  • Not more than once a day.
  • Instruct the patient that sexual stimulation is required for erection to occur.
  • Advise the patient that the drug is not indicated for women.
  • Advise the patient not to concurrently take the drug with nitrates or alpha-adrenergic blockers
  • Instruct the patient if chest pain occurs after taking the drug to report to the PHC practioners immediately.
  • Advise the patient to avoid excess alcohol intake in combination with PDE-5 since it can increase the risk of orthostatic hypotension
TADALAFIL:
  Brand names;
  • Megalis,
  • Tadarich,
  • Tadalis,
  • Cialis and Apcalis 10, 20mg tablets

            It is a more potent and longer acting congener of Sildenafil, duration of action is 24-36 hours. It is claimed to act faster, though peak plasma levels are attained between 30-120minutes.

Indication;
  • Erectile Dysfunction
Mechanism of action
  • As for Sildenafil

Side effects, risks, contraindications and drug interactions are similar to Sildenafil

  • Because of its longer lasting action, nitrates are contraindicated for 36-48hours after Tadalafil.
  • Due to its lower affinity for PDE-6, visual disturbances occur less frequently
Dosage:
  •  10mg o.d. at least 30minutes before sexual intercourse (max 20mg)

Peripheral Initiators of Erection

They include Alprostadil administered intra cavernously (injected) directly into the corpus cavernosum using a fine needle or introduced into the urethra as a small pellet, produces erection in few hours to permit intercourse  .  It is more used in patients taking anti-hypertensive drugs, those with cardiac diseases e.g Coronary artery disease and patients who do not respond to PDE-5 inhibitors.

Mode of Action

It is a prostaglandin E1 analog thus relaxes the penile muscles bringing about erection.

Contraindications
  1.  Presence of any anatomical obstruction or condition that might predispose to priapism. The risk could be exacerbated by these drugs.
  2.  Penile implants.
  3.  Bleeding disorders, CV diseases, optic neuropathy, severe hepatic and renal disorders.
Adverse effects
  • Priapism
  • Thrombo-embolism
  • Local tenderness
  • Penile fibrosis

Central initiators:

 These initiate neuronal path ways for erection e.g.

  • Apomorphine administered orally
Mechanism of action:

Apomorphine is a dopamine agonist  which acts centrally to stimulate an erectile neuronal path way.

It is also for known for Parkinsonism and induction of vomiting thus rarely used for this indication

Adverse effect:
  • Nausea and vomiting
  • Head ache and dizziness
  • Decreased milk production if taken by lactating mothers for another use

Central conditioners:

These provide a central mood condition of erection. They include;

(a). Trazodone which is a CNS anti-depressant due to massive adverse effects

(b). Androgens: e.g. testosterone

Click here to read more about Androgens.

Erectile Dysfunction Medications Read More »

androgens

Androgens

Androgens

Androgens are male sex hormones

Androgens include Testosterone, which is produced in the testes, and the Androgens, which are produced in the Adrenal glands.

Androgens are chiefly produced in the testes and small amounts in adrenal cortex. In female, small amounts are produced in the ovary and adrenal cortex.

        Testosterone is the most important natural androgen and in adult male, 8-10mg is produced daily. Its secretion is regulated by gonadotropins and gonadotrophic releasing Hormone (GnRH).  Inadequate production of androgens is due to pituitary malfunction or atrophy, injury to or removal of testicles. Androgens stimulate the development of male characteristics.

Naturally occurring androgens hormones are;

  • Testosterone, the principal androgenic hormone produced by the leydig cells of the testes.
  • Dehydroepiandrosterone (DHEA) produced by adrenal cortex.

Common Terms

Anabolic steroids: androgens developed with more anabolic or protein-building effects than androgenic effects.
Androgenic effects: effects associated with development of male sexual characteristics and secondary characteristics (e.g., deepening of voice, hair distribution, genital development, acne)
Androgens: male sex hormones, primarily testosterone; produced in the testes and adrenal glands
Hirsutism: hair distribution associated with male secondary sex characteristics (e.g., increased hair on trunk, arms, legs, face)
Hypogonadism: underdevelopment of the gonads (testes in the male)
Penile Erectile Dysfunction: condition in which the corpus cavernosum does not fill with blood to allow for penile erection; can be related to aging or to neurological or vascular conditions

Examples of Androgens

Drug NameUsual DosageUsual Indications
danazol (Danocrine)100–600 mg/d PO, depending on use and responsePrevent ovulation for treatment of endometriosis; prevention of hereditary angioedema
fluoxymesterone (Androxy)5–20 mg/d PO for replacement therapy; 10–40 mg/d PO for certain breast cancersTreatment of delayed puberty in male patients and certain breast cancers in postmenopausal women
testosterone (Androderm, Depo-testosterone)50–400 mg IM every 2–4 weeks, dose varies with preparation (check more below)Replacement therapy in hypogonadism (check more below)
methyltestosterone (Testred, Virilon)Males: 10–50 mg/d PO Females: 50–200 mg/d POReplacement therapy in hypogonadism; treatment of delayed puberty in male patients and certain breast cancers in postmenopausal women

TESTOSTERONE (depo-testerone, androderm) 

Classification:

Therapeutic: Hormone

Pharmacological: Androgen

Pregnancy; Category-x

Schedule: III controlled substance.

Dosage: 50–400 mg IM every 2–4 weeks, dose varies with preparation; some long-acting depository forms are available; dermatological patch 4–6 mg/day, replace patch daily.

Effects of Testosterones.

Anabolic Effects (Growth and Metabolic Functions)

  • Maintains bone density.
  • Regulates fat distribution.
  • Helps in Red Blood Cell production.
  • Supports muscle growth, strength and body mass.
  • Speeds up recovery from injury.
  • They act to increase the retention of nitrogen, sodium, potassium, and phosphorus.
  • They decrease the urinary excretion of calcium.
  • Testosterones increase protein anabolism and
    decrease protein catabolism (breakdown).

Androgenic Effects ( Sexual Characteristics and Functions)

  • Enhances sex drive and libido.
  • Increases aggression.
  • Acne.
  • Beard and body hair.
  • Male pattern boldness.
  • Development and maintenance of male sex organs.
  • Spermatogenesis.
  • Increased size of the prostate.

Control of Testosterone Secretion.

Hypothalamus releases GnRH, which stimulates the Anterior Pituitary gland to secrete FSH an LH which in turn stimulate the Leydig cells to secrete testosterone. High levels of serum testosterone exerts a negative feedback i.e.

  • APG suppresses secretion of LH.
  • Hypothalamus suppresses the GnRH.

Indications of Testosterone.

  1. Hypogonadism and impotence in males due to testicular/pituitary/hypothalamic deficiency.
  2. Testosterone deficiency .
  3. Breast cancer treatment in post menopausal women, who cant be operated.
  4. Treatment of delayed male puberty.
  5. Prevention of postpartum breast engorgement.
  6. Illegally, sportsmen often use anabolic steroids for promoting their musculature and sporting abilities.
  7. Blockage of follicle-stimulating hormone and luteinizing
    response hormone release in women to prevent ovulation for
    treatment of endometriosis.
  8. Prevention of hereditary angioedema

Contraindications of Testosterone.

  •  Allergy to androgens or other ingredients in the drug. Prevent hypersensitivity reactions.
  •  Pregnancy, lactation. Potential adverse effects on the neonate. It is not clear whether androgens enter breast milk.
  •  Presence or history of prostate or breast cancer . Aggravated by the testosterone effects of the drug.
  •  Liver dysfunction, Cardiovascular disease. Can be exacerbated by the effects of the hormones.
  •  Topical forms of testosterone have a Black Box Warning alerting user to the risk of virilization (Female develops male characteristics) in children who come in contact with the drug.
  •  Danazol has Black Box warning regarding the risk of thromboembolic events, fetal abnormalities, hepatitis, and intracranial hypertension.
  • For use with caution in patients with Diabetes Mellitus, BPH and Sleep apnea.

Side Effects and Adverse Effects of Testosterone

                      In men,

  • Administration of an androgen may result in breast enlargement
  • (gynecomastia),
  • testicular atrophy,
  • inhibition of testicular function,
  • impotence,
  • enlargement of the penis,
  • nausea and vomiting,
  • jaundice,
  • headache,
  • anxiety,
  • male pattern baldness,
  • acne and depression,
  • fatigue,
  • abdominal cramps,
  • confusion,
  • deepening of the voice,
  • edema,
  • drug-induced hepatitis,
  • gingivitis.
  • hirsutism (increased hair distribution)

                         In women,

  • receiving an androgen preparation for breast carcinoma the most common adverse reactions are;
  • amenorrhea and virilization (acquisition of male sexual characteristics such as changes in body and facial hair, a deepening voice, acne, menstrual irregularities and enlargement of the clitoris).
Drug Interactions
  1. May increase action of warfarin (anti-coagulants),  oral hypoglycemic agents and insulin.

  2.  Concurrent use with corticosteroids may increase the risk of edema formation.

Nursing intervention/ involvement:

  •  If the androgen is to be administered as a buccal tablet, the nurse demonstrates the placement of the tablet and warns the patient not to swallow the tablet but to allow it to dissolve in the mouth.
  • The nurse reminds the patient not to smoke or drink water until the tablets is dissolved. Oral and parenteral androgens are often taken or given by injection outpatient basis.
  • When given by injection, the injection is administered deep I.M into the gluteus muscle.
  •   Oral testosterone is given with or before meal to decrease gastric upset.
  • When testosterone Trans -dermal system testostederm is prescribed, the nurse places the system on clean, dry scrotal skin. Optimal skin contact of the Trans dermal system is achieved by shaving scrotal hair before placing the system.
  • Monitor fluid input and output
  • Weigh the patient twice a week
  • Assess for edema and report
  • Monitor secondary sexual characteristics in men
  •  Monitor menstrual irregularities, deepening of the voice, in females.
  • Monitor Hemoglobin and hematocrit periodically
  • Monitor urine and serum calcium levels
Patient/family teaching:
  1.  Advise the patient to report signs of priapism, difficulty in urinating, hypercalcemia, edema, unexpected weight gain, swelling of the fee, hepatitis, unusual bleeding.
  2. Explain rationale for prohibiting use of testosterone for increasing athletic performance
  3.   Notify Doctor of pregnancy.
  4.   DM patients to monitor blood sugar.
  5. Regular follow up, laboratory tests and physical examination
  6.  For ladies to notify doctor if signs of body hair distribution, deepening of voice menstrual irregularities occur.

ANABOLIC STEROIDS

 These are agents that are not easily converted to the potent androgen 5 alpha o-dihydrotestosterone (DHT) hence their effects on sex are less but their anabolic effect are high.

Drugs commonly used by athletes include; nandolone, stanozolol, and mithenelone. All of this drugs are regulated as controlled substances, making their use by athletes illegal.

Clinical uses/indications of anabolic steroids.

  • Osteoporosis
  • Appetite improves and there is a feeling of well being.
  • To counteract osteoporosis seen in chronic glucocorticosteroid therapy.
  • Stimulates linear growth in prepubertal boys (height).
  • Used in renal diseases.
NANDROLONE

      This is another steroid naturally produced by body, it is often synthesized and sold under the trade names Deca- Durabolin and Durbolin.

Professional athletes like Berry Bonds and Roger Clemens alleged used nandrolone to illegally enhance their performance.

STANOZOLOL:

       This synthetic steroid goes by the brand name Winstrol. This steroid is unusual in that it can be taken orally. Base ball players like Rafael. Palmeiro have tested positive for illegal use of stanozolol and strength athletes often use it illegally to quickly get stronger.

OXANDROLONE:

          Is a synthetic steroid retailed as the drug Anavar, which is approved for use in osteoporosis. Body builders use this steroid illegally to create greater muscle.

Contraindications:

  • Male patients with cancer of the breast or with known or suspected carcinoma of the prostate.
  • Carcinoma of the breast in female with hypercalcemia; androgenic anabolic steroids may stimulate osteolytic resorption of bones.
  • Pregnant because of masculinization of the fetus.
  • Nephrosis or the nephritic phase of nephritis.

Side effects of anabolic steroids:

  • Severe acne, oily skin and hair – hair loss.(virilization)
  • Liver diseases resulting into complications such as heart attack and stroke.
  • Altered mood, irritability, increased aggression, depression or suicidal tendencies.
  • Alteration in cholesterol and other blood lipids
  • High blood pressure
  • Gynecomastia- abnormal development of mammary glands in men causing breast enlargement.
  • Shrinking of testicles.
  • Azoospermia (absence of sperm in semen)
  • Menstrual irregularities in women
  • Infertility
  • Excess facial or body hair, deeper voice in women.
  • Stunted growth and heat in teens
    risk of viral or bacterial un function due to unsterile injections
  • Edema
  • Prostate cancer
  • Injury from skin-to-skin transfer of topical testosterone

 

Drug interactions:

  • Anti-coagulants. Anabolic steroids may increase sensitivity to oral anti-coagulants. Dosage of the anti-coagulants may have to be decreased in order to maintain the prothrombin time at the desired therapeutic level. Patients receiving oral anti-coagulant therapy require close monitoring, especially when anabolic steroids are started or stopped.

Patient’s information:

  • The physician should instruct patients to report any of the following effects of androgenic anabolic steroids,
  • hoarseness,
  • acne,
  • changes in menstrual periods,
  • more hair on the face,
  • Nausea and vomiting,
  • changes in skin colour or ankle swelling.

ANTI ANDROGENS

Antiandrogens, also known as androgen antagonists or testosterone blockers, are a class of drugs that prevent androgens  from mediating their biological effects in the body.

They act by blocking the androgen receptor and/or inhibiting or suppressing androgen production. They include:

  • Danzol
  • Finasteride
  • Spironolactone
  • Flutamide
  • Cyproterone
  • Ketoconazote
  • Bicalutamide and Nilutamide

Finasteride

Available preparations:      Tablets 5mg

Available brands:                 Finest, Proscar

           The androgen hormone inhibitor finasteride is a synthetic drug that inhibits the conversion of testosterone into the  androgen 5 alpha o-dihydrotestosterone (DHT). The development of the prostate glands is dependent on DHT. The lowering of serum levels of DHT reduces the effect of this hormone on the prostate gland, resulting in decrease in the size of the gland and this synthesis associated with prostate gland enlargement.

Indications;

  • Benign Prostatic Hyperplasia(BPH)
  • Androgenetic alopecia (male pattern baldness) in men only

Mechanism of action:

 It inhibits the enzyme 5-alpha-reductase which is responsible for converting testosterone to its potent metabolite 5-alpha dihydrotestosterone in prostate, liver and skin since 5-alphs dihydrotestosterone is partially responsible for prostatic hyperpiesia and hair loss.

Dose:

  • In BPH 5mg o.d
  • Alopecia 1mg/day for 3 months or more. Available in tablets of mg and 5mg

Side effects;

  • Decreased libido
  • Decreased volume of ejaculation
  • Erectile dysfunction/impotence
  • Breast tenderness and enlargement
  • Testicular pain

Contraindications/precautions;

  • Known hypersensitivity to finasteride
  • Use with caution on hepatic impairment

Nursing implications:

  •   Assess for symptoms of prostatic hyperplasia e.g. feeling of incomplete bladder emptying, interruption of the urinary stream
  •   Digital rectal examination should be done before and periodically during BPH therapy.
  •   Laboratory tests of prostate specific antigen cancer concentration which is used to screen for cancer of prostate.
  • Take this drug without regard to meals.

Patient/ family teaching;

  1. Finasteride possesses risk to male fetus; tell males not to have sex with pregnant women to avoid the risk of absorption
  2. Inform the Doctor immediately if sexual partner is or may become pregnant because additional measures such as discontinuing the drug or use of condom may be necessary.

Androgens Read More »

Uterine Relaxants

Uterine Relaxants

Uterine Relaxants

Uterine Relaxants are drugs which inhibit uterine motility by decreasing the frequency and strength of contractions.

Uterine Relaxants are drugs that inhibit uterine contractions and prolong pregnancy to allow the fetus develop more fully, thereby increasing the chances of neonatal survival.

These drugs prevent premature labor. It can succeed if only the cervical dilatation is less than 4cm.
They include;

  • Salbutamol
  • Magnesium Sulphate
  • Nifedipine
  • Indomethacin
  • Terbutaline

SALBUTAMOL

Legal class; class B controlled drugs
Medical class; tocolysis
Form; tabs , sterile solution for injection
Dosage :tabs 4mg
Soluton for injection 50mg/ ml

Indications
  • Uncomplicated premature labour between 24 to 33 weeks of gestation
  • Asthma
Contraindications
  •  Cardiac diseases
  • APH
  • Intra uterine fetal death.
  • Intra uterine infections
  • Raptured membranes
  • Eclampsia and pre-eclampsia
  • 1st an 2nd trimester of pregnancy
Dose
  • For premature labour, intravenous, infusion 10mcg/ min, gradually increase according to response at 10 minutes intervals until contractions diminish, then increase rate until contractions have ceased, max dose : 45mcg/min
  • Maintain rate for 1hr then gradually reduce by intravenous or intramuscular injection 100-250mg repeated according to response, then orally 4mg every 6-8hrs
    Do not use for more than 48minutes
Side effects
  •  Hypoglycemia
  • Vomiting and nausea
  • Sweating
  • Tremors
  • Hypotension
  • Pulmonary oedema
  • Maternal and fetal tachycardia
  • Headache
  • Palpitations
  • Urticaria

Magnesium Sulphate ( MgSO4)

Legal class; class B controlled drugs
Medical class; tocolytic and anticonvulsant
Form; sterile solution for injection
Strength/dosage; 50% of 5 grams/10ml

uterine relaxants magnesium sulphate

Dosage
Loading dose (14g)

4g of MgSO are given slowly intravenously for over 15 to 20 minutes and is prepared as follows

  1. Take a 20ml syringe and draw 8 mils if 50% MgSO4 (4g)
  2. Add 12 mils of water for injection to make 20% of the solution
  3. Give intravenously slowly over 15 minutes.

Immediately this is followed by 10g intramuscular and  is  prepared as follows;

  1. Take 20mils syringe, draw 10mils of 50% MgSO4 (undiluted) which is equivalent to 5g in each syringe
  2. Then add one mil of 2% lignocaine in each syringe to reduce pain
  3. Give deep intramuscular on each buttock
Maintenance Dose

Give 5g of 50% MgSO4 deep intramuscular on alternate buttocks every 4hrs prepare as below.

  1. Take 10ml syringe and draw 10ml of 50% of MgSO4 (5g).
  2. Add 1ml of lignocaine 2% in a syringe and give deep intramuscular.
    The dose can be repeated after every 4hrs of alternate buttock.
  3. The treatment is continued for 24hrs from the time of starting treatment or last fit.
    >  Incase the mother gets fit before 4hours, she is given 2g slowly intravenous.
Useful Effects of MgSO4:
  • Prevent seizures which are associated with pre eclampsia and eclampsia
  • Reduces cerebral oedema
  • Relieves constipation by retaining some water in the lumen
Indications
  •  Severe eclampsia and pre eclampsia
  • Patients with hypomagnesemia
  • Patients with severe asthma
  • Used in short term treatment of constipation
  • Patients with myocardial infarction
Contraindications
  •  Patients with hypermagnesemia
  • Patients who are hypersensitive to MgSO4
  • Renal impairment
  • Hepatic failure
  • Hypotensive patients
  • Patients with epilepsy
Side effects
  •  Drop in blood pressure
  • Flushing of the skin
  •  Dizziness
  •  Confusion
  •  Muscle weakness
  •  Loss of knee jack reflex
  •  Prolonged bleeding time
  •  Excessive bowel activity
Adverse effects
  •  Shock in hypertensive patients
  • Hypermagnesemia
  • Respiratory depression and coma

NIFIDIPINE

Legal class; class B controlled drugs
Medical class; tocolytic and antihypertensive
Form; tablet


Dosage
  •  20mg and the dose is repeated after 30minutes if contractions persists.
  • If contractions continue after 3hrs give 20mg every 3-8hrs until ceased and the maximum dose is 160mg/day

Indications
  •  Threatened abortion
  • Preterm labour less than 34wks of pregnancy
  • Hypertension

Contraindications
  •  Maternal conditions like cardiac diseases
  •  Hypertension
  •  Intrauterine infections
  •  Any condition that make pregnancy to prolong
  •  Fetal death

Side effects
  •  Dizziness
  • Headache
  • Flushing
  • Oedema
  • Fatigue

Uterine Relaxants Read More »

Drugs used in labor

Drugs used in Labor

Drugs used in Labour

Drugs used in labour can be grouped according to the effect they have on the uterus.

  1. Uterine Stimulants/Uterine Mortility drugs. (Oxytocics)
  2. Uterine relaxants (Tocolytics)

Uterine Stimulants/Uterine Motility Drugs(Oxytocics)

Uterine motility drugs stimulate uterine contractions to assist labor (oxytocics) or induce abortion (abortifacients)

Oxytocics

Oxytocics stimulate contraction of the uterus, much like the action of the hypothalamic hormone oxytocin, which is stored in the posterior pituitary. These drugs include

  • Ergonovine (Ergotrate)
  • Methylergonovine (Methergine)
  • Oxytocin (Pitocin, Syntocinon).

Oxytocin

Legal class; class B controlled drugs
Medical class; oxytocic drugs
Form; sterile solution for injection
Strength; 10 IV per ampule.

Indications of Oxytocin
  1.  Induction of labor
  2.  Cases of inter-uterine fetal death.
  3.  Hypotonic uterine contractions
  4.  Mothers with hypertension
  5.  After delivery to control bleeding
  6. Pre-eclampsia and eclampsia
  7.  Congestive cardiac failure
  8.  Post term
  9. Prevent PPH
  10. Incomplete or missed abortion.
  11. Active management of third stage of labor.

Contraindications of Oxytocin
  •  Hypertonic uterine
  •  Fetal and maternal distress
  •  Multiple pregnancy
  •  Trial of labor
  •  Mal presentation like breech, brow
  •  Cephalo pelvic disproportion
  •  Low blood pressure
Dose
  1. Induction/argumentation of labour;  5 I.U into 500mls of solution for infusion, initially, 5 drops per min.
  2. Preventing of PPH after delivery of the placenta; Slow I.V, 5 I.U, increase rate during 3rd stage.

Route
  •  Intramuscular
  • Intravenously when mixed with normal saline or dextrose

Side Effects
  •  Dizziness
  • Nausea and vomiting
  • Rashes
  • Fetal brandy cardia
  • Hypotension

Adverse Effects
  •  Lead to ruptured uterus
  • Hypotension
  • Tachycardia
  • Intra uterine fetal anoxia and hypoxia to the fetus leading to birth asphyxia.
Pharmacokinetics
  •  Absorption is immediate following IV injections
  • Drug is distributed throughout the extracellular fluid. Some amount enters the fetal circulation.
  • It is metabolized rapidly in kidney and liver in small amount and are excreted in urine

Abortifacients

Abortifacients are used to evacuate uterine contents via intense uterine contractions. These drugs include;

  • Misoprostol
  • Carboprost (Hemabate)
  • Dinoprostone (Cervidil, Prepidil Gel, Prostin E2)
  • Mifepristone ( Mifeprex). 

Misoprostol

Legal class; class B controlled drugs
Medical class; oxytocic drugs/ cervical, rippening agent
Form; tablet
Strength; 200mcg/ 100mcg tablet

Indications
  •  Induction of labour
  • Control post partum hemorrhage due to uterine atony
  • Before cervical dilatation
  • Intra-uterine fetal death
  • Gastric and deudenal ulcerations
Contraindications
  •  Mal presentation
  • Placeta previa grade 3 and 4
  • Multiparous mothers
  • Cephalo pelvic disproportion
  • Hypersensitivity to misoprostol
Dose
  • Induction of labour; 100mcg vaginally every after 12hrs
  • NSAID ulcerations; 200mcg 4 times a day
Route
  • Sublingually
  • Rectally
  • Vaginally
Side Effects
  • Headache
  • Dizziness
  • Fever
  • Shivering
  • Vomiting
  • Uterine rupture
  • Fetal distress.
  • Constipation
Pharmacokinetics.

Absorbed in the GIT and distributed widely through out the body metabolised in the liver and is excreted in urine.

DINOPROSTOL

Available preparation – 3mg tab
Available brand – Prostin

Pharmacokinetics

Following vaginal insertion, it diffused slowly into the maternal blood.
There is also some local absorption into the uterus through the cervix
It is distributed widely in the molter, metabolized in the lungs, liver, kidney, spleen and other maternal tissues and excreted in urine with small amount in faeces.

Indications
  • Induction of labor
  • Missed abortion
Contraindications
  •  Active cardiac diseases
  • Multiple pregnancy
  • Hypersentivity to dinoprostol
  • Untreated pelvic infection
  • Caesarian section

Dose :  3 mg vaginally

Side Effects
  •  Abdominal pain
  • Nausea and vomiting
  • Hypotension
  • Shivering
  • Back pain
  • Rapid cervical dilatation

SYNTOMETRINE

Legal class; class B controlled drugs
Medical class; oxytocic drug
Form; sterile solution for injection
Strength; combination of ergometrine and Pitocin ( ergometrine 0.5 mg + Pitocin 5 IU) –It exists in an ampules of 1 mill

Dose
  • I ml as single dose but can be repeated where necessary if bleeding is not controlled
Route
  •    Intramuscular
  •    Intravenous
Indications
  1.  Give to multi gravidas after delivery
  2.   Mothers with a history of post partum hemorrhage
  3. Multiple or twin delivery because of large placental site
  4. Mothers with heavy lochia
  5. Abortion when fundal height is less than 12 weeks
Contraindications

Mothers with cardiac disease, pre eclampsia, eclampsia and hypertension.

Adverse Effects
  •  Retained placenta
  •  IUFD in undiagnosed second twin
  • Lead to retained 2nd twin
  • Uterine rapture if given in abortion, above 20 weeks of gestation products of conception are not fully out.
  • Causes hypoxia and anoxia
Side Effects
  • Nausea and vomiting
  • Headache
  • Hypotension
  • Dyspnea
  • Muscle pain

ERGOMETRINE

Legal class; class B controlled drugs
Medical class; oxytocic drug
Form; tablet and sterile solution
Strength/dosage; tabs 0.25 to 0.5mg tab
Injection 200mcg/ml
0.5mg/ml
EFFECTS
It causes sudden prolonged intermittent uterine contraction
INDICATION
Contra indications
Side effects
Dangers
(Are the same as for syntometrine)

Drugs used in Labor Read More »

Fertility Drugs/ Gonadotropin Drugs drugs

Fertility Drugs/Gonadotropin Drugs

Fertility Drugs

Fertility drugs are drugs that stimulate the female reproductive system.

Examples of Fertility drugs;

  • Cetrorelix (Cetrotide)
  • Chorionic gonadotropin (Chorex, Profasi, Pregnyl).
  • Chorionic gonadotropin alpha (Ovidrel).
  • Clomiphene (Clomid)
  • Menotropins
    (Pergonal, Humegon).

Therapeutic Actions and Indications.

Women without primary ovarian failure who cannot get pregnant after 1 year of trying may be candidates for the use of fertility drugs. Fertility drugs work either directly to stimulate follicles and ovulation or stimulate the hypothalamus to increase FSH and LH levels, leading to ovarian follicular development and maturation of ova.

Indications

  1. Given in sequence with human chorionic gonadotropin (HCG) to maintain the follicle and hormone production, these drugs are used to treat infertility in women with functioning ovaries whose partners are fertile.
  2. Fertility drugs also may be used to stimulate multiple follicle development for the harvesting of ova for in vitro fertilization.
  3. Menotropins also stimulate spermatogenesis in men with low sperm counts and otherwise normally functioning testes.
  4. Cetrorelix inhibits premature LH surges in women undergoing controlled ovarian stimulation by acting as a GnRH antagonist.
  5. Chorionic gonadotropin is used to stimulate ovulation by acting like GnRH and affecting FSH and LH release.

Contraindications of fertility drugs

  1. Allergy to fertility drug:  Prevent hypersensitivity.
  2.  Primary ovarian failure: These drugs only work to stimulate functioning ovaries
  3. Thyroid or adrenal dysfunction. Drugs have effects on the hypothalamic-pituitary axis.
  4. Ovarian cysts: Can be stimulated by the drugs and can become larger
  5. Pregnancy: Due to the potential for serious fetal effects
  6. Idiopathic uterine bleeding: Can represent an underlying problem that could be exacerbated by the stimulatory effects of these drugs.
  7. Lactation: Risk of adverse effects on the baby
  8. Thromboembolic disease. Increased risk of thrombus formation
  9. Women with respiratory diseases: Alterations in fluid volume and blood flow can overtax the respiratory system.

Adverse effects of fertility drugs

  • Greatly increased risk of multiple births and birth defects
  • Ovarian overstimulation: abdominal plain, distention, ascites, pleural effusion
  • Headache
  • Fluid retention
  • Nausea
  • Bloating
  • Uterine bleeding
  • Ovarian enlargement
  • Gynecomastia
  • Febrile reactions possibly due to stimulation of progesterone release.

Fertility Drugs

DrugIndicationDose
Clomifene Anovulatory infertility50mg daily for 5 days, starting within 5 days of onset of menstruation (preferably on the second day) or at any time if cycles have ceased
Bromocriptine Hyper prolactanaemic, infertility, Suppression of lactation, Hypogonadism, Galactorrhoea syndrome, Benign breast diseaseInitially 1.25mg at bed time increased gradually to the usual dose of 2.5mg 3 times a day with food increased if necessary to a max. dose 30mgdaily

Nursing Diagnosis

  • Acute pain related to headache, fluid retention, or GI upset
  • Sexual dysfunction related to alterations in normal hormone control
  • Disturbed body image related to drug treatment and diagnosis
  • Deficient Knowledge regarding drug therapy
  •  Risk for Impaired Tissue Perfusion (Cardiopulmonary, Peripheral) related to increased risk for thrombus formation
  •  Situational Low Self-Esteem related to the need for fertility drugs.

Fertility Drugs/Gonadotropin Drugs Read More »

Estrogen Receptor Modulators

Estrogen Receptor Modulators

Estrogen Receptor Modulators

Estrogen Receptor Modulators are agents that either stimulate or block specific estrogen receptor sites.

They are used to stimulate specific estrogen receptors to achieve therapeutic effects of increased bone mass without stimulating the endometrium and causing other less desirable effects i.e. these drugs stimulate the estrogen receptors in the body so as to produce estrogen as needed by the body.

Examples of Estrogen Receptor Modulators.

Two available estrogen receptor modulators are raloxifene (Evista) and toremifene (Fareston).

Raloxifene

Dose : 60 mg/day Orally.

Indications : Used therapeutically to stimulate specific estrogen receptor sites, which results in an increase in bone mineral density without stimulating the endometrium in women; reduces risk of invasive breast cancer in  postmenopausal women with osteoporosis who are at
high risk for invasive breast cancer

Toremifene

Dose : 60 mg/day orally until disease progression occurs.

Indications: Used as an antineoplastic agent because of its effects on estrogen receptor sites for treatment of advanced breast cancer in postmenopausal women with estrogen receptor–positive and estrogen
receptor–unknown tumors

Contraindications of Estrogen Receptor Modulators
  • Allergy to estrogen receptor modulators.
  • Contraindicated in pregnancy and lactation because of potential effects on the fetus or neonate. 
  •  History of venous thrombosis or smoking. Increased risk of blood clot formation if smoking and estrogen are combined.
Adverse Effects of Estrogen Receptor Modulators
  • Raloxifene has been associated with GI upset, nausea, and vomiting.
  • Changes in fluid balance may cause headache, dizziness, visual changes, and mental changes.
  • Specific estrogen receptor stimulation may cause hot flashes, skin rash, edema, and vaginal bleeding.
Clinically Important Drug–Drug Interactions
  •  Cholestyramine: reduced raloxifene absorption
  • Highly protein-bound drugs (e.g. diazepam, ibuprofen, indomethacin, naproxen): interference on binding sites
  • Warfarin: decreased prothrombin time if taken with raloxifene

Nursing Considerations

  1.  Assess for the mentioned cautions and contraindications (e.g. drug allergies, cardiovascular diseases, metabolic bone disease, history of thromboembolism, etc.) to prevent any complications.
  2. Perform a thorough physical assessment (e.g. bowel sounds, skin assessment, vital signs, mental status, etc.) to establish baseline data before drug therapy begins, to determine effectiveness of
    therapy, and to evaluate for occurrence of any adverse effects associated with drug therapy.
  3. Assist with pelvic and breast examinations. Ensure specimen collection for Pap smear and obtain a history of patient’s menstrual cycle to provide baseline data and to monitor for any adverse
    effects that could occur.
  4. Arrange for ophthalmic examination especially for patients who are wearing contact lenses because hormonal changes can alter the fluid in the eye and curvature of the cornea, which can
    change the fit of contact lenses and alter visual acuity.
  5. Monitor laboratory test results (e.g. urinalysis, renal and hepatic function tests, etc.) to determine possible need for a reduction in dose and evaluate for toxicity.

Nursing Diagnoses
  •  Ineffective tissue perfusion related to changes in the blood vessels brought about by drug therapy and risk of thromboemboli
  • Excess fluid volume related to fluid retention
  • Acute pain related to systemic side effects of gastrointestinal (GI) pain and headache


Implementation with Rationale
These are vital nursing interventions done in patients who are taking female sex hormones and estrogen receptor modulators:

  •  Administer drug with food to prevent GI upset.
  • Provide analgesic for relief of headache as appropriate.
  • Provide small, frequent meals to assist with nausea and vomiting.
  • Monitor for swelling and changes in vision or fit of contact lenses to monitor for fluid retention and fluid changes.
  • Provide comfort measures to help patient tolerate drug effects.
  • Provide safety measures (e.g. adequate lighting, raised side rails, etc.) to prevent injuries.
  • Educate client on drug therapy to promote understanding and compliance.


Evaluation

Here are aspects of care that should be evaluated to determine effectiveness of drug therapy:

  •  Monitor patient response to therapy (palliation of signs and symptoms of menopause, prevention of pregnancy, decreased risk factors for coronary artery disease, and palliation of certain cancers).
  • Monitor for adverse effects (e.g. GI upset, edema, changes in secondary sex characteristics, headaches, thromboembolic episodes, and breakthrough bleeding).
  • Evaluate patient understanding on drug therapy by asking patient to name the drug, its indication, and adverse effects to watch for.
  • Monitor patient compliance to drug therapy

Estrogen Receptor Modulators Read More »

Fertility Drugs/ Gonadotropin Drugs drugs

Gonadotropin drugs

GONADOTROPINS

Gonadotropins are fertility medications given by injection that contain follicle-stimulating hormone (FSH) alone or combined with luteinizing hormone (LH).

Gonadotropins are hormones that stimulate the gonads, which are the sex organs in the body

Gonadotropins are produced by the pituitary gland, which is a small gland located at the base of the brain. The release of gonadotropins is regulated by the hypothalamus.

 

In females, the gonads are the ovaries, and in males, they are the testes.

Gonadotropins are a class of medications used to treat infertility and disorders associated with reproductive functions.

Types of Gonadotropins

There are two main types of gonadotropins:

1. Follicle-stimulating hormone (FSH): This hormone stimulates the growth and development of follicles in the ovaries of females and sperm production in the testes of males.

Females

Males

– Normal Ovarian Function: FSH is useful for the development and maturation of follicles in the ovaries, which contain the eggs. This ensures regular ovulation and fertility.

– Estrogen Production: FSH stimulates the production of estrogen by the growing follicles. Estrogen is for the development of female secondary sexual characteristics, menstrual cycle regulation, and overall reproductive health.

– Improved Egg Quality: FSH contributes to the development of healthy eggs, increasing the chances of successful fertilization and pregnancy.

– Fertility Treatment: FSH is a key component of fertility treatments like in vitro fertilization (IVF) to stimulate multiple egg production.

– Sperm Production: FSH is essential for the production of sperm in the testes. It stimulates the Sertoli cells, which are responsible for nourishing and supporting sperm development.

– Improved Sperm Quality: FSH contributes to the production of healthy, motile sperm, increasing the chances of fertilization.

2. Luteinizing hormone (LH): This hormone triggers ovulation in females and testosterone production in males.

Females

Males

– Ovulation: LH triggers the release of the mature egg from the follicle (ovulation), which is essential for fertilization.

– Corpus Luteum Formation: After ovulation, LH stimulates the formation of the corpus luteum, which produces progesterone. Progesterone is for maintaining the uterine lining for potential pregnancy.

– Hormonal Balance: LH plays a role in regulating the production of estrogen and progesterone, contributing to hormonal balance in the female body.

– Fertility Treatment: LH is used in fertility treatments to trigger ovulation and support the development of the corpus luteum.

– Testosterone Production: LH stimulates the Leydig cells in the testes to produce testosterone. Testosterone is essential for male sexual development, sperm production, and overall health.

– Secondary Sexual Characteristics: LH-driven testosterone production is responsible for the development of male secondary sexual characteristics like facial hair, muscle mass, and deepening of the voice.

– Libido and Sexual Function: Testosterone, produced under the influence of LH, plays a crucial role in libido and sexual function.

GONADOTROPIN DRUGS (Fertility Drugs)

Gonadotropin Drugs/Fertility drugs are agents that stimulate the female reproductive system.

Fertility drugs are medications used to help women who are having trouble getting pregnant. They work by stimulating the ovaries to produce more eggs, increasing the chances of conception.

Indications for Fertility Drugs:

1. Treatment of infertility in women with functioning ovaries whose partners are fertile: This is a broad category encompassing various causes of infertility, including:

  • Anovulation: When a woman doesn’t ovulate regularly, fertility drugs can stimulate ovulation and increase the chances of pregnancy.
  • Polycystic Ovarian Syndrome (PCOS): PCOS often causes irregular ovulation. Fertility drugs can help regulate ovulation and improve fertility.
  • Endometriosis: This condition can affect ovulation and egg quality. Fertility drugs can help stimulate ovulation and improve chances of conception.
  • Premature Ovarian Failure: In some cases, women experience premature ovarian failure, leading to low egg reserves. Fertility drugs can help stimulate limited egg production.
  • Unexplained Infertility: When the cause of infertility is unknown, fertility drugs can be used to stimulate ovulation and see if it improves chances of pregnancy.

2. Used to stimulate multiple follicle development for harvesting of ova for in vitro fertilization (IVF): This is a crucial aspect of IVF, where multiple eggs are needed for fertilization and embryo transfer.

3. Menotropins are used to stimulate spermatogenesis in men with low sperm counts and otherwise normally functioning testes: While not directly related to female fertility, this highlights the broader application of fertility drugs in both men and women.

Contraindications for Fertility Drugs:
  1. Allergy to fertility drug: Prevent hypersensitivity reactions.
  2. Primary ovarian failure: These drugs only work to stimulate functioning ovaries.
  3. Ovarian cysts: Can be stimulated by the drugs and can become larger.
  4. Pregnancy: Due to the potential for serious fetal effects.
  5. Idiopathic uterine bleeding: Can represent an underlying problem that could be exacerbated by the stimulatory effects of these drugs.
  6. Lactation: Risk of adverse effects on the baby.
  7. Thromboembolic disease: Increased risk of thrombus formation.
  8. Women with respiratory diseases: Alterations in fluid volume and blood flow can overtax the respiratory system.
Adverse Effects:
  • Greatly increased risk of multiple births and birth defects.
  • Ovarian overstimulation: abdominal pain, distention, ascites, pleural effusion.
  • Others: headache, fluid retention, nausea, bloating, uterine bleeding, ovarian enlargement, gynecomastia, and febrile reactions possibly due to stimulation of progesterone release.
  • Fluid retention is a common side effect of fertility medications, because;

    Hormonal Changes: Fertility drugs increase estrogen levels, which can lead to fluid retention. Estrogen promotes sodium retention in the body, and sodium attracts water, causing fluid buildup.

    Increased Blood Flow: Fertility drugs increase blood flow to the ovaries and uterus, which can lead to fluid buildup in the pelvic area.

Drugs used in treatment of infertility

Name

Clinical uses and dosage

Contraindications

Clomifene


  • Available in tablet form of 50mg

  • Brand name Clomid

Infertility due to failure to ovulate.

Given 50 mg daily × 5/7

Starting from the 5th day of the cycle ,

Increase to 100mg ×5/7

From day 5-10 if no response.

Pregnancy.

Bromocriptine


  • Available in tablet form of 2.5mg

Female infertility associated with hyperprolactinemia

Dosage 1.25 – 2.5mg

Bid × 3-7 days with food.

Inhibition of lactation 2.5mg bid with meals × 14 days.

 

Severe ischemic heart disease

Uncontrolled hypertension

Pregnancy

Breast feeding.

FEMALE REPRODUCTIVE SYSTEM DRUGS

Drugs that affect the female reproductive system typically include hormones and hormonal-like agents.

These drug types include;

  1.  Female Sex Hormones
  2. Estrogen Receptor Modulators
  3. Fertility Drugs/gonadotropins
  4. Drugs used in labor
  5. Abortifacients
gonadotropin sites

Gonadotropin Sites of Action

Female Sex Hormones

The female sex hormones can be used to replace hormones that are missing or to act on the control mechanisms of the endocrine system to decrease the release of endogenous hormones.
Drugs that act like estrogen, particularly at specific estrogen receptors, are also used to stimulate the effects of estrogen in the body with fewer of the adverse effects.

Female sex hormones include;

  • Estrogens 
  • Progestins

Estrogens.

This hormone is naturally produced by the ovaries, placenta and adrenal glands. It stimulates the development of female sex characteristics, prepares the body for pregnancy, affects the release of FSH and LH, and is responsible for proliferation of the endometrial lining.

Low estrogen in the body is responsible for the signs and symptoms of menopause, in the uterus, vagina, breast and cervix.

Other Functions of estrogen include;

  1. Breast development.
  2. Increase cholesterol in bile, to prevent damaging effects of bile salts.
  3. Increases fat storage, such as in breast tissue.
  4. Maintains bone mineral density.
  5. Maintains muscle strength.
  6. Prevents atherosclerosis, by increasing HDL concentration and lowering LDL.
  7. Estrogen is responsible for maintaining libido, memory, and mental health. 
  8. It stimulates ovulation, maintains the uterine walls and is important in vaginal lubrication.
Indications of Estrogen Therapy.
  • Estrogens are used for hormone replacement therapy (HRT) when ovarian activity is blocked or absent.
  • Is used to control the signs and symptoms of menopause.
  • They can also be used in therapy for prostate cancer and inoperable breast cancer, also as palliative care.
  • Treatment of female hypogonadism(when the body produces little or no hormones).
  • Treat ovarian failure.
  • Oral contraceptives (estrogen and progestin)
  • Morning after pill (emergency pills)
  • Endometriosis
  • Dysmenorrhea, used with progestin.

Progestin/Progesterone.

This promotes maintenance of pregnancy and it is called a pregnancy hormone.

Its functions include;

  1. Transforms proliferative endometrium into secretory endometrium.
  2. Prevents follicle maturation, ovulation and uterine contractions.
  3. Used in contraceptives. It inhibits release of GnRH, FSH and LH, hence follicle development and ovulation are prevented.
Indications of Progestin.
  • Used as a contraceptive.
  • Maintains pregnancy and development of secondary sex characteristics.
  • Use to treat primary and secondary amenorrhea, and functional uterine bleeding.
  • Treatment of acne and premenstrual dysphoric disorder (PMDD).
  • For the relief of signs and symptoms of menopause .
Contraindications of Female Sex hormones.

Estrogen

  • Known allergies
  • Idiopathic vaginal bleeding.
  • Breast Cancer(Estrogen dependant cancer)
  • CVA since it increases clotting factor prodn.
  • Hepatic dysfunction.
  • Pregnancy.
  • Lactation.

Progestin/Progesterone

  • PID
  • STD
  • Endometriosis
  • Renal and hepatic disorders.
  • Epilepsy.
  • Asthma.
  • Migraine headaches
  • Cardiac Dysfunction —potential excerbation.
Adverse Effects.
  • Corneal Changes.
  • Photosensitivity.
  • Peripheral edema.
  • Chloasma ( patches on the face)
  • Hepatic adenoma.
  • Nausea
  • Vomiting.
  • Abdominal cramps.
  • Bloating.
  • Withdraw bleeding.
  • Changes in menstrual flow.

Important aspects/issues to remember.

  1.  Women receiving any of these drugs should receive an annual medical examination, including
    breast examination and Pap smear, to monitor for adverse effects and underlying medical
    conditions.
  2. Women taking estrogen should be advised not to smoke because of the increased risk of
    thrombotic events.
  3. Women who are receiving these drugs for fertility programs should receive a great deal of psychological support and comfort measures to cope with the many adverse effects associated
    with these drugs. The risk of multiple births should be explained.
  4. Drugs are used in treatment of specific cancers in males and they should be advised about the
    possibility of estrogenic effects.
  5. Not indicated during pregnancy or lactation because of potential for adverse effects on the fetus
    or neonate.
Examples of female sex hormones and dosages.

Estrogen

  1. Estradiol, 1–2 mg/day orally or  1–5 mg IM every 3–4 weeks or  2–4 g intravaginal cream daily.
  2. Estrogens, conjugated (C.E.S., Premarin), 0.3–1.25 mg/day orally.
  3. Estropipate (Ortho-Est, Ogen), 0.625–5 mg/day orally.

Progestin/Progesterone.

  1. Etonogestrel (Implanon) 68 mg implanted sub dermally for up to 3 yr, replaced or changed when needed.
  2. Medroxyprogesterone (Provera) 5–10 mg/day PO for 5–10 days for amenorrhea or 400–1000 mg/week IM for cancer therapy or 150 mg of deep IM every 3 months (13 weeks) for contraception.
Clinically important Drug Interactions

Estrogen

  •  Barbiturates, rifampin, tetracyclines, phenytoin: decreased serum estrogen levels
  • Corticosteroids: increased therapeutic and toxic effects of corticosteroids.
  • Nicotine: Increased risk of thrombi and emboli
  • Grapefruit juice: inhibition of metabolism of estradiols
  • St. John’s wort: can affect metabolism of estrogens and can make estrogen-containing
    contraceptives less effective.

Progestins

  •  Barbiturates, carbamazepine, phenytoin, griseofulvin, penicillin, tetracyclines, rifampin: reduced
    effectiveness of progestins
  • St. John’s wort: can affect the metabolism of progestins and can make progestin-containing
    contraceptives less effective..

Gonadotropin drugs Read More »

pneumonia in children

Pneumonia in Children

Pediatric Pneumonia Lecture Notes
Pediatric Pneumonia

Pneumonia remains a leading cause of morbidity and mortality in children worldwide, especially in developing countries. Its epidemiology and etiology differ significantly from adults, largely due to variations in immune system maturity, exposure patterns, and anatomical differences.

Pneumonia is an acute inflammatory condition of the lung parenchyma caused by an infection.

  • lung parenchyma is the the functional tissue of the lungs, specifically the alveoli and bronchioles.

This inflammation leads to the filling of the alveolar spaces with exudate, cells, and fluid, a process known as consolidation. This consolidation impairs gas exchange, leading to symptoms such as cough, fever, chills, and difficulty breathing.

In simpler terms, pneumonia is an infection that inflames the air sacs in one or both lungs. The air sacs may fill with fluid or pus (purulent material), causing cough with phlegm or pus, fever, chills, and trouble breathing.

Classifications of Pneumonia

Pneumonia can be classified in various ways, each providing a different lens through which to understand its cause, presentation, and management.

A. By Etiology (Cause of Infection):

This classification focuses on the specific microorganism responsible for the infection.

  1. Bacterial Pneumonia: The most common type, often more severe than viral pneumonia.
    • Common Pathogens:
      • Streptococcus pneumoniae (Pneumococcus): The most frequent cause of community-acquired bacterial pneumonia.
      • Haemophilus influenzae.
      • Staphylococcus aureus (including MRSA).
      • Klebsiella pneumoniae.
      • Mycoplasma pneumoniae (often called "walking pneumonia" due to milder symptoms).
      • Chlamydophila pneumoniae.
      • Legionella pneumophila (Legionnaires' disease).
  2. Viral Pneumonia: Often milder than bacterial pneumonia but can be severe, especially in infants, elderly, and immunocompromised individuals.
    • Common Pathogens:
      • Influenza viruses (Types A and B).
      • Respiratory Syncytial Virus (RSV).
      • Adenoviruses.
      • Parainfluenza viruses.
      • Human Metapneumovirus.
      • Coronaviruses (e.g., SARS-CoV, MERS-CoV, SARS-CoV-2).
  3. Fungal Pneumonia: Less common, usually affecting individuals with weakened immune systems or those exposed to large amounts of fungi in the environment.
    • Common Pathogens:
      • Pneumocystis jirovecii (PCP pneumonia, common in HIV/AIDS patients).
      • Histoplasma capsulatum (Histoplasmosis).
      • Coccidioides immitis (Coccidioidomycosis or Valley Fever).
      • Blastomyces dermatitidis (Blastomycosis).
      • Aspergillus species.
  4. Parasitic Pneumonia: Rare, caused by parasites, usually seen in immunocompromised individuals or those who have traveled to endemic areas.
    • Common Pathogens:
      • Toxoplasma gondii.
      • Strongyloides stercoralis.
  5. Aspiration Pneumonia: Occurs when foreign material (e.g., food, liquid, vomit, stomach contents) is inhaled into the lungs, leading to inflammation and often secondary bacterial infection.
    • Causes: Impaired swallowing mechanisms, altered consciousness, gastroesophageal reflux.
  6. Chemical Pneumonia (Pneumonitis): Lung inflammation caused by inhaling irritating chemicals or toxic gases, rather than an infectious agent. This is not an infection but can predispose to one.
    • Causes: Inhalation of smoke, noxious fumes, or gastric acid.
B. By Anatomical Location (Area of Lung Affected):

This classification describes the pattern of lung involvement as seen on chest imaging.

  1. Lobar Pneumonia: Affects a large, continuous area of an entire lobe of a lung. Often caused by Streptococcus pneumoniae.
    • Appearance: Typically seen as a dense, homogeneous consolidation on chest X-ray.
  2. Bronchopneumonia (or Lobular Pneumonia): Characterized by patchy consolidation centered around the bronchi and bronchioles, often affecting multiple lobes. More common in infants, young children, and the elderly.
    • Appearance: Patchy infiltrates on chest X-ray, often bilateral and basal.
  3. Interstitial Pneumonia: Involves the interstitial spaces of the lung (the tissue between the alveoli and capillaries), rather than primarily the air sacs. More commonly associated with viral or atypical bacterial infections.
    • Appearance: Reticular or reticulonodular patterns on chest X-ray.
  4. Miliary Pneumonia: A form of pneumonia characterized by the wide dissemination of an infectious agent (Mycobacterium tuberculosis) throughout the lung tissue in small, discrete lesions resembling millet seeds.
    • Appearance: Fine, diffuse nodular infiltrates throughout both lungs on chest X-ray.
C. By Duration:

This classification refers to the time course of the illness.

  1. Acute Pneumonia: Rapid onset and progression of symptoms, typically resolving within days to a few weeks with appropriate treatment. Most common form.
  2. Chronic Pneumonia: Persistent symptoms and radiological findings lasting for weeks to months, or even longer. Often associated with specific pathogens (e.g., Mycobacterium tuberculosis, fungi) or underlying conditions.
D. By Clinical Grounds / Acquisition Setting:

This is one of the most clinically relevant classifications, as it guides initial empiric treatment decisions.

  1. Community-Acquired Pneumonia (CAP): Pneumonia acquired outside of hospitals or long-term care facilities.
    • Common Pathogens: Streptococcus pneumoniae, Mycoplasma pneumoniae, Chlamydophila pneumoniae, Haemophilus influenzae, influenza virus.
  2. Hospital-Acquired Pneumonia (HAP) / Nosocomial Pneumonia: Pneumonia that develops 48 hours or more after hospital admission and was not incubating at the time of admission.
    • Common Pathogens: Often more virulent and antibiotic-resistant bacteria, such as Pseudomonas aeruginosa, Staphylococcus aureus (MRSA), Klebsiella species, Escherichia coli.
  3. Ventilator-Associated Pneumonia (VAP): A subtype of HAP that develops in patients who have been mechanically ventilated for more than 48 hours.
    • Common Pathogens: Similar to HAP, often highly resistant organisms.
Etiology of Pneumonia

The etiology refers to the specific agents or organisms responsible for causing pneumonia. As discussed in Objective 1, these can be broadly categorized.

A. Common Bacterial Pathogens:

These are the most frequent causes of pneumonia, especially bacterial pneumonia.

  1. Streptococcus pneumoniae (Pneumococcus):
    • Description: The leading cause of community-acquired bacterial pneumonia (CAP) in all age groups, particularly in adults.
    • Characteristics: Gram-positive coccus, typically arranged in pairs (diplococci). Has a polysaccharide capsule that protects it from phagocytosis.
    • Risk Factors: Old age, chronic lung disease, recent viral infection, immunocompromised status.
  2. Haemophilus influenzae:
    • Description: A common cause of both CAP and HAP, especially in individuals with chronic obstructive pulmonary disease (COPD) or other underlying lung conditions.
    • Characteristics: Gram-negative coccobacillus.
    • Risk Factors: COPD, cystic fibrosis, alcoholism.
  3. Staphylococcus aureus:
    • Description: Can cause severe pneumonia, often seen as HAP or as a complication of viral infections (e.g., influenza). Methicillin-resistant S. aureus (MRSA) is a significant concern, especially in VAP and HCAP.
    • Characteristics: Gram-positive coccus, often arranged in clusters. Produces various toxins.
    • Risk Factors: Recent influenza, injection drug use, skin/soft tissue infection, hospitalization, surgical procedures.
  4. Klebsiella pneumoniae:
    • Description: A common cause of HAP and, less frequently, severe CAP, particularly in individuals with alcoholism or diabetes. Known for causing "currant jelly" sputum.
    • Characteristics: Gram-negative rod, often encapsulated.
    • Risk Factors: Alcoholism, diabetes, chronic lung disease, hospitalization.
  5. Pseudomonas aeruginosa:
    • Description: A significant cause of HAP and VAP, particularly in immunocompromised patients, those with cystic fibrosis, or prolonged hospital stays. Difficult to treat due to antibiotic resistance.
    • Characteristics: Gram-negative rod.
    • Risk Factors: Cystic fibrosis, bronchiectasis, mechanical ventilation, broad-spectrum antibiotic use, immunocompromised state.
  6. Mycoplasma pneumoniae:
    • Description: A common cause of "atypical pneumonia" or "walking pneumonia" in young adults and school-aged children. Causes milder, but prolonged, symptoms.
    • Characteristics: Lacks a cell wall, making it resistant to many common antibiotics (e.g., penicillin).
  7. Chlamydophila pneumoniae:
    • Description: Another cause of atypical pneumonia, often with milder symptoms.
    • Characteristics: Obligate intracellular bacterium.
  8. Legionella pneumophila:
    • Description: Causes Legionnaires' disease, a severe form of pneumonia often associated with contaminated water sources (e.g., air conditioning systems, hot tubs).
    • Characteristics: Gram-negative rod, fastidious growth requirements.
B. Common Viral Pathogens:

Viruses are a very common cause of pneumonia, especially in children. They can also predispose to secondary bacterial infections.

  1. Influenza Viruses (A and B): Seasonal epidemics cause widespread respiratory illness, including primary viral pneumonia and often secondary bacterial pneumonia.
  2. Respiratory Syncytial Virus (RSV): The most common cause of lower respiratory tract infections in infants and young children, often leading to bronchiolitis and pneumonia.
  3. Adenoviruses: Can cause a range of respiratory illnesses, including pneumonia, particularly in children and immunocompromised individuals.
  4. Parainfluenza Viruses: Common cause of croup, but can also cause bronchiolitis and pneumonia, especially in children.
  5. Coronaviruses (e.g., SARS-CoV-2): Various coronaviruses can cause respiratory infections, with SARS-CoV-2 (COVID-19) being a notable cause of severe viral pneumonia and acute respiratory distress syndrome (ARDS).
C. Common Fungal Pathogens:

More prevalent in immunocompromised individuals or specific geographic regions.

  1. Pneumocystis jirovecii: Causes Pneumocystis pneumonia (PCP), a common and severe opportunistic infection in individuals with HIV/AIDS.
  2. Endemic Fungi (e.g., Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis): Found in specific geographic areas. Exposure to spores can lead to pneumonia, especially in immunocompromised individuals.
  3. Aspergillus species: Can cause invasive aspergillosis, a severe pneumonia, primarily in severely immunocompromised patients (e.g., transplant recipients, leukemia patients).
D. Aspiration of Gastric Contents/Foreign Material:

Not an infectious agent itself, but the aspiration of acidic gastric contents or other foreign material can cause a severe chemical pneumonitis, which then often becomes secondarily infected by oral flora (anaerobic bacteria).

Pathogenesis of Pneumonia

Pathogenesis describes the sequence of events that leads to the development of pneumonia, from initial exposure to clinical symptoms.

A. Normal Host Defenses:

The respiratory tract has several protective mechanisms to prevent infection:

  1. Upper Airway Filtration: Nasal hairs, turbinates, and mucous membranes filter out large particles.
  2. Epiglottis and Cough Reflex: Protect the lower airways from aspiration.
  3. Mucociliary Escalator: Ciliated epithelial cells line the trachea and bronchi, moving mucus (which traps pathogens) upwards for expectoration or swallowing.
  4. Alveolar Macrophages: Phagocytic cells in the alveoli that engulf and destroy pathogens and debris.
  5. Humoral and Cellular Immunity: Antibodies (IgA, IgG) and T lymphocytes provide specific immunity.
Mechanisms of Pathogen Entry:

Pneumonia develops when pathogens overcome or bypass these host defenses.

  1. Aspiration (Most Common): Microaspiration of oropharyngeal secretions containing pathogens is the most frequent route. This happens constantly in small amounts, but typically the host defenses clear them. Impaired consciousness, dysphagia, or presence of a nasogastric tube increases the risk of significant aspiration.
  2. Inhalation: Airborne pathogens (e.g., viruses, Mycoplasma, Legionella, fungi) can be inhaled directly into the lower respiratory tract.
  3. Hematogenous Spread: Pathogens from a distant site of infection (e.g., endocarditis, IV drug use, abdominal sepsis) can travel through the bloodstream to the lungs.
  4. Direct Spread: Less common, but can occur from contiguous infected sites (e.g., empyema spreading to lung, trauma).
Pathophysiology:

Once pathogens reach the lower respiratory tract and evade local defenses, a series of events leads to inflammation and consolidation:

  1. Colonization and Multiplication: Pathogens colonize the alveoli and/or terminal bronchioles and begin to multiply.
  2. Immune Response and Inflammation:
    • Alveolar Macrophages: Are typically the first line of defense. If overwhelmed, they release cytokines (e.g., TNF-alpha, IL-1, IL-6, IL-8).
    • Neutrophil Recruitment: These cytokines attract neutrophils from the bloodstream into the alveolar spaces.
    • Increased Vascular Permeability: The inflammatory response causes vasodilation and increased permeability of the alveolar-capillary membrane.
  3. Fluid Exudation and Consolidation:
    • Plasma fluid, red blood cells, and fibrin leak into the alveolar spaces.
    • Neutrophils and bacteria fill the alveoli.
    • This mixture of fluid, cells, and debris leads to the characteristic consolidation seen in pneumonia, where the lung tissue becomes dense and airless.
  4. Impaired Gas Exchange:
    • The consolidated alveoli can no longer participate in gas exchange.
    • This leads to ventilation-perfusion mismatch (areas are perfused but not ventilated), resulting in hypoxemia (low blood oxygen).
    • The increased work of breathing due to decreased lung compliance and airway obstruction can also lead to hypercapnia (high blood carbon dioxide) in severe cases.
  5. Tissue Damage: The inflammatory process and release of bacterial toxins can cause damage to the alveolar and bronchial epithelial cells, impairing mucociliary function and further propagating inflammation.
  6. Resolution: With effective immune response and/or antibiotic treatment, the inflammation subsides, macrophages clear cellular debris, and the exudate is reabsorbed, allowing the lung to return to normal function.
Etiology of Pediatric Pneumonia (Causative Agents)

The pathogens responsible for pneumonia vary significantly by age group.

A. Neonates (Birth to 1 Month):
  • Pneumonia in neonates is often acquired perinatally (from the mother during birth) or nosocomially (in the hospital).
  • Bacterial:
    • Group B Streptococcus (GBS): Common cause of early-onset neonatal sepsis and pneumonia.
    • Gram-negative enteric bacilli: Escherichia coli, Klebsiella pneumoniae.
    • Listeria monocytogenes.
  • Viral: Less common primary cause, but can be involved (e.g., Herpes Simplex Virus - HSV).
  • B. Infants (1 Month to 6 Months):
  • Transition period, with a mix of perinatal pathogens and increasing community-acquired pathogens.
  • Bacterial:
    • Streptococcus pneumoniae (pneumococcus): Increasingly common.
    • Haemophilus influenzae (non-typeable or type b if unvaccinated).
    • Staphylococcus aureus: Can cause severe disease.
  • Atypical Bacteria:
    • Chlamydia trachomatis: Can cause afebrile pneumonia, often associated with conjunctivitis, transmitted from mother during birth. Presents at 2-12 weeks of age.
    • Bordetella pertussis (whooping cough): Can cause severe pneumonia, especially in unvaccinated infants.
  • Viral (Most Common Overall):
    • Respiratory Syncytial Virus (RSV): The leading cause of bronchiolitis and pneumonia in infants.
    • Parainfluenza viruses: (Types 1, 2, 3).
    • Adenovirus: Can cause severe and prolonged disease.
    • Influenza viruses: (A and B).
    • Human Metapneumovirus.
  • C. Preschool Children (6 Months to 5 Years):
  • Viral (Still Most Common):
    • RSV, Influenza, Parainfluenza, Adenovirus, Human Metapneumovirus, Rhinovirus.
  • Bacterial:
    • Streptococcus pneumoniae (Pneumococcus): Remains the most frequent bacterial cause.
    • Haemophilus influenzae (non-typeable).
    • Staphylococcus aureus (including MRSA).
    • Streptococcus pyogenes (Group A Strep): Less common but can cause severe pneumonia.
  • Atypical Bacteria:
    • Mycoplasma pneumoniae: Becomes more common in this age group, though classically associated with school-aged children.
  • D. School-Aged Children and Adolescents (> 5 Years):
  • The spectrum of pathogens begins to resemble that of adults.
  • Atypical Bacteria (Increasingly Common):
    • Mycoplasma pneumoniae: The most common cause of "atypical pneumonia" or "walking pneumonia."
    • Chlamydophila pneumoniae.
  • Bacterial:
    • Streptococcus pneumoniae.
    • Staphylococcus aureus (including MRSA).
    • Haemophilus influenzae.
    • Streptococcus pyogenes.
  • Viral:
    • Influenza A and B.
    • Adenovirus.
  • E. Less Common but Important Causes (Across Age Groups):
  • Tuberculosis (Mycobacterium tuberculosis): Consider in endemic areas or with risk factors.
  • Fungal Pneumonia: (e.g., Pneumocystis jirovecii pneumonia - PCP) primarily in immunocompromised children.
  • Aspiration Pneumonia: In children with feeding difficulties, GERD, or neurological impairment.
  • Clinical Presentation of Pneumonia in Children

    Recognize age-specific manifestations and indicators of severity to ensure timely intervention.

    I. General Signs and Symptoms of Pneumonia in Children
  • Cough: May be dry, moist, or productive (though young children rarely expectorate sputum). Can sometimes be the only prominent symptom.
  • Tachypnea (Increased Respiratory Rate): Often the most sensitive and specific sign of pneumonia in children, especially in infants. Defined as:
    • < 2 months: ≥ 60 breaths/min
    • 2-11 months: ≥ 50 breaths/min
    • 1-5 years: ≥ 40 breaths/min
    • 5 years: ≥ 20 breaths/min
  • Fever: Present in many cases, but can be absent, especially in neonates, young infants, or immunocompromised children.
  • Dyspnea (Difficulty Breathing): Manifested as increased work of breathing.
  • Lethargy / Irritability: Non-specific signs of illness in children.
  • Poor Feeding / Decreased Oral Intake: Common in infants and young children.
  • Chest Pain: More common in older children, often pleuritic (sharp, worse with breathing).
  • Abdominal Pain: Can be referred pain from diaphragmatic irritation, especially in lower lobe pneumonia.
  • II. Age-Specific Clinical Manifestations
    A. Neonates (Birth to 1 Month):
  • Pneumonia in neonates is often subtle and non-specific, making diagnosis challenging.
  • Non-specific Signs:
    • Respiratory Distress: Tachypnea (often the earliest sign), grunting, nasal flaring, retractions (subcostal, intercostal, suprasternal).
    • Apnea: Pauses in breathing, especially in premature infants.
    • Cyanosis (bluish discoloration) or pallor.
    • Lethargy, irritability, hypotonia.
    • Poor feeding, vomiting.
    • Temperature instability (hypothermia is common, fever less so).
    • Jaundice.
  • Physical Exam: May reveal decreased breath sounds, crackles (rales), or wheezing.
  • B. Infants (1 Month to 1 Year):
  • More overt signs of respiratory illness are typically present.
  • Key Signs:
    • Tachypnea: Always a critical sign.
    • Retractions: Subcostal, intercostal, suprasternal, supraclavicular.
    • Nasal Flaring.
    • Grunting: Short, low-pitched sounds during expiration, attempting to increase end-expiratory pressure.
    • Cough: Can be prominent, may be paroxysmal, especially with Pertussis or viral causes like RSV.
    • Fever.
    • Poor feeding, decreased activity.
    • Wheezing (more common with viral pneumonia/bronchiolitis).
  • Physical Exam: Crackles, decreased breath sounds, dullness to percussion (if consolidation is significant).
  • C. Toddlers and Preschoolers (1 Year to 5 Years):
  • Similar to infants, but with more verbal communication of symptoms.
  • Key Signs:
    • Tachypnea.
    • Cough: Often harsh and persistent.
    • Fever.
    • Dyspnea, increased work of breathing.
    • Lethargy, irritability, decreased playfulness.
    • Decreased appetite.
    • Abdominal pain: Can be a presenting complaint, particularly with lower lobe pneumonia irritating the diaphragm.
  • Physical Exam: Crackles, rhonchi, decreased breath sounds, dullness to percussion.
  • D. School-Aged Children and Adolescents (> 5 Years):
  • Clinical presentation begins to resemble adult pneumonia.
  • Key Signs:
    • Cough: Can be productive with sputum, especially in bacterial pneumonia.
    • Fever and Chills.
    • Dyspnea / Shortness of Breath.
    • Pleuritic Chest Pain: Sharp pain worsened by breathing or coughing.
    • Headache, malaise, myalgia.
    • Abdominal pain.
    • "Atypical" Pneumonia (e.g., Mycoplasma pneumoniae): Often presents with more insidious onset, low-grade fever, persistent dry cough, headache, and malaise, sometimes called "walking pneumonia."
  • Physical Exam: Crackles, egophony, decreased breath sounds, dullness to percussion.
  • III. Indicators of Severe Pneumonia / Respiratory Distress in Children

    Rapid recognition of these signs is critical for determining the need for hospitalization and intensive care.

  • Inability to Feed/Drink: Especially in infants and young children.
  • Severe Respiratory Distress:
    • Severe Tachypnea (respiratory rate significantly above age-appropriate limits).
    • Severe Retractions (all types, especially supraclavicular, tracheal tug).
    • Grunting.
    • Nasal Flaring.
    • Central Cyanosis: Bluish discoloration of the tongue, lips, and nail beds, indicating hypoxemia.
    • Head Bobbing: Especially in infants.
  • Altered Mental Status: Lethargy, extreme irritability, difficult to arouse, confusion.
  • Hypoxemia: SpO2 < 90% (or lower, depending on altitude and clinical context) on room air.
  • Signs of Dehydration.
  • Signs of Shock: Tachycardia, poor perfusion, hypotension (a late sign in children).
  • Diagnostic Approaches for Pneumonia in Children
    Clinical Assessment (The Most Important Step):
  • History:
    • Onset and duration of symptoms (fever, cough, respiratory distress, feeding difficulties).
    • Exposure history (sick contacts, daycare, travel).
    • Vaccination status.
    • Risk factors (prematurity, underlying medical conditions).
    • Medication history.
  • Physical Examination:
    • General Appearance: Alertness, activity level, signs of distress.
    • Vital Signs: Respiratory rate (most sensitive sign of pneumonia), heart rate, temperature, blood pressure.
    • Respiratory Examination:
      • Inspection: Work of breathing (retractions, nasal flaring, grunting), cyanosis, symmetry of chest movement.
      • Palpation: Tactile fremitus (may be increased over consolidation, but difficult in young children).
      • Percussion: Dullness over consolidated areas or pleural effusion.
      • Auscultation:
        • Crackles (rales): Suggestive of alveolar inflammation/fluid.
        • Bronchial breath sounds: Over consolidated lung tissue.
        • Wheezing: More common in viral causes or with underlying reactive airway disease.
        • Decreased or absent breath sounds: May indicate consolidation or pleural effusion.
    • Other Systems: Assess for dehydration, cardiac involvement, neurological status.
  • Pulse Oximetry:
    • Essential non-invasive test in all children suspected of having pneumonia.
    • Measures oxygen saturation (SpO2). Hypoxemia (SpO2 < 90-92% on room air) is a strong indicator of severity and often guides hospitalization and oxygen therapy.
    Chest Radiography (CXR):
  • Indications:
    • Typically not recommended for routine diagnosis of uncomplicated community-acquired pneumonia in children who can be managed as outpatients and whose diagnosis is clear clinically.
    • Recommended for:
      • Children with severe pneumonia.
      • Uncertain diagnosis, or if differential diagnoses like foreign body aspiration are considered.
      • Failure to respond to initial empiric therapy.
      • Suspicion of complications (e.g., pleural effusion, empyema, abscess).
      • Recurrent pneumonia.
  • Findings:
    • Lobar Consolidation: Suggests bacterial pneumonia.
    • Interstitial Infiltrates: More characteristic of viral or atypical pneumonia.
    • Bronchial Wall Thickening/Peribronchial Cuffing: Common in viral infections.
    • Pleural Effusion, Empyema, Pneumothorax: Indicate complications.
    • Hyperinflation: Common in viral bronchiolitis.
  • Limitations:
    • Cannot reliably distinguish between bacterial and viral pneumonia.
    • Poor correlation between radiological findings and clinical severity.
    • Radiation exposure.
  • Laboratory Tests:
  • Blood Cultures:
    • Generally NOT recommended for routine CAP in outpatient settings.
    • Consider for: Hospitalized children with severe pneumonia, immunocompromised children, suspicion of bacteremia. Low yield (typically < 1-2%).
  • Complete Blood Count (CBC) with Differential:
    • Not routinely recommended for uncomplicated CAP.
    • May show leukocytosis with neutrophilia in bacterial infection, or lymphocytosis in viral infection, but findings can overlap and are not definitive.
  • Inflammatory Markers (e.g., C-reactive protein (CRP), Procalcitonin):
    • May be elevated in bacterial infections, but also in severe viral infections.
    • Not routinely used for initial diagnosis but can sometimes aid in differentiating bacterial from viral, or monitoring response to treatment.
  • Viral Diagnostics (e.g., Nasopharyngeal Swabs for PCR):
    • Recommended for: All hospitalized infants and young children with suspected viral pneumonia/bronchiolitis (e.g., RSV, influenza, adenovirus, parainfluenza).
    • Important for infection control, cohorting patients, and avoiding unnecessary antibiotic use.
    • Does not rule out bacterial co-infection.
  • Sputum Culture:
    • Difficult to obtain in young children, often contaminated by upper airway flora. Not routinely recommended.
  • Pleural Fluid Analysis:
    • If pleural effusion is present, diagnostic thoracentesis may be performed to identify the pathogen and guide treatment for empyema.
  • Tuberculin Skin Test (TST) / Interferon-Gamma Release Assay (IGRA):
    • Consider in children with persistent or recurrent pneumonia, or risk factors for tuberculosis.
  • Serology for Atypical Pathogens (e.g., Mycoplasma pneumoniae, Chlamydia pneumoniae):
    • Can be useful for retrospective diagnosis, but acute and convalescent titers are needed, so not helpful for acute management.
  • Differential Diagnoses

    Many conditions can mimic pneumonia in children due to similar respiratory symptoms.

    1. Upper Respiratory Tract Infection (URI) / Common Cold: Often presents with cough, rhinorrhea, low-grade fever. Absence of tachypnea and significant work of breathing usually differentiates it from pneumonia.
    2. Bronchiolitis: Common in infants < 2 years, primarily caused by RSV. Presents with cough, rhinorrhea, tachypnea, prominent wheezing, and crackles. Often difficult to distinguish clinically from viral pneumonia, and they can coexist.
    3. Asthma Exacerbation / Reactive Airway Disease: Wheezing, cough, dyspnea. History of recurrent episodes or triggers may point to asthma.
    4. Foreign Body Aspiration: Sudden onset of choking, coughing, dyspnea, particularly in toddlers. Can lead to unilateral wheezing or recurrent localized pneumonia. A high index of suspicion is needed. CXR may show unilateral hyperinflation or atelectasis.
    5. Croup (Laryngotracheobronchitis): "Barking" cough, inspiratory stridor, hoarseness, typically worse at night. Primarily affects the upper airway.
    6. Pertussis (Whooping Cough): Prolonged paroxysmal cough, often followed by a "whooping" sound and post-tussive emesis. Can cause severe pneumonia in infants.
    7. Heart Failure: Tachypnea, cough, poor feeding, hepatomegaly, often in infants with congenital heart disease. CXR may show cardiomegaly and pulmonary edema.
    8. Pulmonary Edema: Can result from fluid overload, acute kidney injury, or cardiac dysfunction.
    9. Pleural Effusion (without underlying pneumonia): Can cause dyspnea and decreased breath sounds, but usually related to other causes (e.g., malignancy, autoimmune disease).
    10. Tuberculosis: Consider in endemic areas or with risk factors, especially for persistent cough, failure to thrive, or abnormal CXR.
    Medical Management for Pediatric Pneumonia

    Aims: The medical management of pediatric pneumonia aims to eradicate the causative pathogen, alleviate symptoms, prevent complications, and provide supportive care tailored to the child's age and severity of illness.

    I. General Principles of Management
    1. Assessment of Severity: The initial step is to assess the severity of pneumonia to determine the appropriate level of care (outpatient vs. inpatient, general ward vs. ICU). Key indicators include respiratory distress (tachypnea, retractions, grunting, nasal flaring), hypoxemia (SpO2 < 90-92%), inability to feed, lethargy, and signs of dehydration.
    2. Empiric Antibiotic Therapy:
      • Rationale: While viral etiologies are common, bacterial pneumonia can be severe and life-threatening. Clinical signs often overlap, and rapid viral testing may not be immediately available. Therefore, empiric antibiotic treatment is crucial, especially in moderate to severe cases, to cover likely bacterial pathogens.
      • De-escalation: Once a pathogen is identified (e.g., strong evidence of viral infection) or if the child rapidly improves, antibiotics may be discontinued or narrowed.
    3. Supportive Care: This is the cornerstone of management for all types of pneumonia (viral and bacterial) and focuses on maintaining oxygenation, hydration, nutrition, and comfort.
    II. Specific Management Strategies
    A. Antimicrobial Therapy (Based on your provided text and general guidelines):

    The choice of antibiotic depends on the child's age, severity of illness, local resistance patterns, and immunization status.

    1. For Infants under 2 months with Severe Pneumonia (Hospitalized):
      • First-line combination: Ampicillin (150-200 mg/kg/day in divided doses IV) plus Gentamycin (5-6 mg/kg/day IV).
        • Rationale: Covers common neonatal pathogens like Group B Streptococcus and Gram-negative enteric bacilli.
      • Alternative if Penicillin Not Available/Suitable: Cefotaxime (IV).
      • If Condition Does Not Improve/Suspicion of S. aureus: Add Cloxacillin (IV) to cover Staphylococcus aureus.
      • Duration: Typically 10 days, but can be individualized based on clinical response and pathogen.
    2. For Older Children 2 months to 5 years (Hospitalized with Severe Pneumonia):
      • First-line: Ceftriaxone (IV, 50-100 mg/kg/day once daily) or Ampicillin plus Gentamycin.
        • Rationale: Ceftriaxone provides broad-spectrum coverage against Streptococcus pneumoniae and Haemophilus influenzae. Ampicillin + Gentamycin is an alternative.
      • Consideration for Atypical Pathogens (e.g., Mycoplasma): If atypical pneumonia is suspected (e.g., persistent cough, gradual onset, older child), a macrolide (e.g., Azithromycin) may be added or used alone depending on clinical suspicion and local guidelines.
      • Duration: Typically 7-10 days.
    3. For Children with Non-Serious Pneumonia (Outpatient Management):
      • First-line: Amoxicillin (oral, 80-90 mg/kg/day divided twice daily).
        • Rationale: Effective against Streptococcus pneumoniae, the most common bacterial cause in this age group, and has a good safety profile.
      • Alternative if Amoxicillin Allergy or Suspected Atypical Pathogen: Macrolide (e.g., Azithromycin, Erythromycin) may be considered.
      • Duration: Typically 5-7 days for uncomplicated cases.
    B. Symptomatic Management and Supportive Care:
    1. Fever Management:
      • Paracetamol (Acetaminophen): Administer for fever (and pain) as per weight-based dosing.
      • Tepid Sponging: Can be used as an adjunctive measure if the child is uncomfortable or has very high fever, but should not be the sole method of fever reduction and can cause discomfort.
      • Goal: Improve comfort and reduce metabolic demands, not necessarily to normalize temperature.
    2. Respiratory Support:
      • Positioning: Nurse patient in a semi-sitting up position or with the head elevated to aid breathing and improve lung expansion.
      • Airway Clearance:
        • Nasal Irrigation: With 0.9% sodium chloride to clear nasal passages, especially important in neonates and infants who are obligate nasal breathers.
        • Assisted Coughing/Suctioning: If the child is unable to clear secretions effectively. Suctioning should be performed gently and only when necessary to avoid trauma or laryngospasm.
        • Chest Physiotherapy (CPT) / Chest Exercises: Can be helpful, especially in cases with significant secretions or atelectasis, but evidence for routine use in uncomplicated pneumonia is mixed.
      • Monitoring for Increased Respiratory Distress: Continuous assessment of respiratory rate, work of breathing, and oxygen saturation is paramount.
      • Bronchodilators: Administer bronchodilators (e.g., inhaled salbutamol) if there is evidence of bronchospasm or significant wheezing, especially in children with a history of asthma or bronchiolitis.
      • Oxygen Therapy:
        • Indication: Administer oxygen where hypoxemia (SpO2 < 90-92% on room air) or cyanosis has occurred.
        • Delivery Methods: Nasal cannula, oxygen mask, high-flow nasal cannula (HFNC) for more severe cases.
        • Goal: Maintain SpO2 > 90-92% (or higher, depending on clinical scenario).
    3. Fluid and Nutritional Support:
      • Hydration: Promote adequate rehydration.
        • Oral Fluids: Encourage frequent sips of oral fluids (water, breast milk, rehydration solutions) as tolerated.
        • Intravenous (IV) Fluids: In children with severe respiratory difficulty, vomiting, or inability to take oral fluids, place an IV line and give fluids cautiously. Typically, start with 70-80% of normal maintenance fluids to avoid fluid overload, which can worsen pulmonary edema. Resume oral fluids as soon as possible.
      • Nutrition:
        • Breastfeeding on Demand: For infants, if they are able to suck effectively and without severe respiratory distress. Breast milk provides vital antibodies and nutrients.
        • Well-Balanced Nutrition: For older children. If oral intake is poor due to dyspnea or fatigue, nasogastric tube (NGT) feeding may be necessary to ensure adequate caloric and fluid intake.
    C. General Care and Monitoring:
    1. Observations: Regular and frequent monitoring of respiratory rate, temperature, heart rate, and oxygen saturation is essential to assess response to treatment and detect deterioration.
    2. Hygiene: Maintain good personal and environmental hygiene to prevent further infections and transmission.
    3. Keep Patient Warm and Dry: Ensure comfortable body temperature and clean, dry clothing/bedding.
    4. Change Position: Regularly change the patient's position to prevent skin breakdown, promote lung expansion, and facilitate secretion drainage.
    5. Rest: Provide adequate rest periods to conserve the child's energy.
    6. Pain Management: Treat any associated pain (e.g., pleuritic chest pain) with analgesics like paracetamol or ibuprofen.
    Nursing Diagnoses for Pediatric Pneumonia

    These diagnoses guide the nurse in identifying patient needs and planning individualized care.

    1. Ineffective Airway Clearance related to increased tracheobronchial secretions, ineffective cough (especially in young children), and inflammation, as evidenced by adventitious breath sounds (crackles, rhonchi), ineffective or absent cough, nasal flaring, tachypnea, dyspnea, pallor/cyanosis, poor feeding.
    2. Impaired Gas Exchange related to alveolar-capillary membrane changes (inflammation, exudate), ventilation-perfusion mismatch, as evidenced by tachypnea, dyspnea, hypoxemia (SpO2 < 90-92%), cyanosis, restlessness/irritability/lethargy, abnormal blood gases.
    3. Ineffective Breathing Pattern related to inflammation, pain (pleuritic), and fatigue, as evidenced by tachypnea, dyspnea, use of accessory muscles, shallow respirations, retractions, grunting.
    4. Risk for inadequate Fluid Volume related to fever, increased insensible fluid loss (tachypnea), decreased oral intake, and vomiting, as evidenced by dry mucous membranes, decreased urine output, poor skin turgor, sunken fontanelles (infants), absent tears.
    5. Inadequate protein energy intake related to anorexia, dyspnea, fatigue, increased metabolic needs, and difficult feeding, as evidenced by reported inadequate intake, weight loss/poor weight gain, refusal to eat/drink, fatigue during feeding.
    6. Hyperthermia related to infectious process and increased metabolic rate, as evidenced by elevated body temperature, flushed skin, tachycardia, tachypnea, irritability.
    7. Acute Pain related to inflammation of lung parenchyma/pleura or generalized body aches, as evidenced by verbal reports of pain (older child), grimacing, guarding, restlessness, crying, irritability, withdrawal.
    8. Activity Intolerance related to imbalance between oxygen supply and demand, generalized weakness, and fatigue, as evidenced by verbal reports of fatigue (older child), decreased play/activity, exertional dyspnea, abnormal heart rate/blood pressure response to activity.
    9. Excessive Anxiety (Child/Parent) related to dyspnea, threat to health status, hospitalization, unfamiliar environment, and fear of unknown outcomes, as evidenced by restlessness, crying, apprehension, irritability, verbalization of concerns.
    10. Inadequate Health Knowledge (Parents) related to disease process, treatment regimen, home care, and prevention, as evidenced by questions, inaccurate follow-through of instructions, verbalization of concerns.
    Specific Nursing Interventions for Pediatric Pneumonia

    These interventions are tailored to the child's age and developmental stage, focusing on gentle, non-threatening approaches.

    A. For Ineffective Airway Clearance / Impaired Gas Exchange / Ineffective Breathing Pattern:
    Intervention Detail/Rationale
    1. Continuous Respiratory Assessment Monitor respiratory rate, depth, rhythm, effort (retractions, nasal flaring, grunting), breath sounds, SpO2 (continuous pulse oximetry is often used), skin color (for cyanosis) every 1-4 hours or more frequently as needed.
    2. Positioning Place the child in a semi-Fowler's position (head of bed elevated 30-45 degrees) or position of comfort to promote lung expansion. Avoid positions that might impede breathing.
    3. Airway Management
    • Nasal Care: Perform nasal saline irrigation and gentle suctioning, especially before feeds and sleep, for infants and young children to clear nasal passages.
    • Encourage Coughing: For older children, encourage deep breathing and effective coughing. For younger children, provide chest physiotherapy (percussion, vibration) as prescribed, followed by suctioning or assisted coughing if appropriate, to mobilize secretions.
    • Suctioning: Perform gentle nasopharyngeal or oropharyngeal suctioning only when necessary to remove visible secretions that the child cannot clear. Use appropriate catheter size and technique to avoid trauma.
    4. Oxygen Therapy
    • Administer warmed, humidified oxygen via nasal cannula, mask, hood, or tent as prescribed, to maintain SpO2 > 90-92%.
    • Monitor oxygen flow rate and ensure patency of delivery device.
    • Minimize crying and agitation to conserve oxygen.
    5. Administer Medications Give bronchodilators, antibiotics, and other prescribed respiratory medications (e.g., corticosteroids) on time and monitor for effectiveness and side effects.
    6. Maintain Hydration Ensure adequate hydration to thin secretions. (See Fluid and Nutrition section).
    B. For Risk for Inadequate Fluid Volume / Inadequate protein energy intake:
    Intervention Detail/Rationale
    1. Monitor Fluid Balance Strictly monitor intake (oral, IV, NGT) and output (urine, stools, emesis). Assess for signs of dehydration (e.g., dry mucous membranes, sunken fontanelles, poor skin turgor, decreased urine output).
    2. Promote Hydration
    • Oral: Offer small, frequent amounts of preferred clear fluids (e.g., Pedialyte, water, diluted juice). For infants, encourage frequent, shorter breastfeeds or formula feeds if tolerated.
    • IV Fluids: Administer IV fluids as prescribed, monitoring for signs of overhydration (e.g., crackles, edema).
    3. Optimize Nutrition
    • Small, Frequent Meals: Offer small, frequent, nutrient-dense meals or snacks.
    • Rest Before Feeds: Allow rest periods before feeding to conserve energy.
    • NGT/OGT Feeding: If the child has significant respiratory distress, is unable to feed orally, or is losing weight, administer feeds via nasogastric or orogastric tube as prescribed.
    • Consult Dietitian: For specialized nutritional assessment and planning.
    C. For Hyperthermia / Acute Pain:
    Intervention Detail/Rationale
    1. Monitor Temperature Assess temperature regularly.
    2. Fever Management
    • Administer antipyretics (e.g., Paracetamol, Ibuprofen) as prescribed, ensuring correct dose based on weight.
    • Remove excessive clothing, use lightweight blankets.
    • Tepid sponging may be used if the child is uncomfortable, but avoid chilling.
    3. Pain Assessment Use age-appropriate pain scales (e.g., FLACC scale for non-verbal children, Faces Pain Scale for older children).
    4. Pain Management
    • Administer analgesics (e.g., Paracetamol, Ibuprofen) as prescribed.
    • Utilize non-pharmacological methods: comfort positioning, distraction (toys, stories, music), parental presence, gentle touch.
    D. For Activity Intolerance:
    Intervention Detail/Rationale
    1. Balance Rest and Activity Organize care to allow for uninterrupted rest periods.
    2. Encourage Age-Appropriate Activity Gradually increase activity as tolerated, monitoring for signs of fatigue or respiratory distress.
    3. Assist with ADLs Provide assistance with activities of daily living as needed to conserve energy.
    E. For Excessive Anxiety (Child/Parent):
    Intervention Detail/Rationale
    1. Child
    • Provide a calm, reassuring presence.
    • Use age-appropriate language to explain procedures.
    • Allow comfort items (e.g., blanket, toy) and parental presence.
    • Use distraction techniques during procedures.
    2. Parents
    • Provide clear, consistent information about the child's condition, treatment plan, and prognosis.
    • Answer questions honestly and empathetically.
    • Encourage participation in care, as appropriate.
    • Address their fears and concerns, and provide emotional support.
    • Refer to social work or spiritual care if needed.
    F. For Inadequate Health Knowledge (Parents):
    Intervention Detail/Rationale
    1. Assess Learning Needs Determine what parents already know and what information they need.
    2. Educate on
    • Disease Process: What pneumonia is, what to expect during recovery.
    • Medications: Name, purpose, dose, frequency, side effects, importance of completing full antibiotic course.
    • Home Care: How to manage fever, cough, recognize worsening symptoms, return precautions (when to seek medical attention).
    • Nutrition and Hydration: Importance of maintaining intake, encouraging small, frequent feeds.
    • Prevention: Hand hygiene, avoiding sick contacts, importance of immunizations (influenza, PCV, Hib).
    • Follow-up: Importance of follow-up appointments.
    3. Teach-Back Method Have parents demonstrate or verbalize understanding of key information.
    4. Provide Written Materials For reinforcement.
    Prevention Strategies for Pediatric Pneumonia

    Effective prevention can significantly reduce the global burden of this disease.

    I. Vaccination

    Vaccines are one of the most effective tools in preventing severe pneumonia and its complications in children.

    1. Pneumococcal Conjugate Vaccine (PCV):
      • Targets: Streptococcus pneumoniae, the leading bacterial cause of pneumonia, meningitis, and sepsis in children.
      • Impact: Dramatically reduced the incidence of invasive pneumococcal disease and pneumonia in vaccinated children and, through herd immunity, in unvaccinated individuals.
      • Recommendation: Universal vaccination for infants, typically administered in a series of doses (e.g., PCV13, PCV15, PCV20 depending on national guidelines).
    2. Haemophilus influenzae type b (Hib) Vaccine:
      • Targets: Haemophilus influenzae type b, another significant bacterial cause of pneumonia, meningitis, and epiglottitis.
      • Impact: Led to a near elimination of invasive Hib disease in vaccinated populations.
      • Recommendation: Universal vaccination for infants, typically administered in a series of doses.
    3. Influenza (Flu) Vaccine:
      • Targets: Seasonal influenza viruses (Type A and B), which can directly cause viral pneumonia or predispose to secondary bacterial pneumonia.
      • Impact: Reduces the risk of influenza illness, hospitalizations, and deaths.
      • Recommendation: Annual vaccination for all children 6 months of age and older, especially those with underlying chronic conditions.
    4. Measles, Mumps, Rubella (MMR) Vaccine:
      • Targets: Measles virus, which can cause severe pneumonia directly and also predispose to secondary bacterial pneumonia due to its immunosuppressive effects.
      • Impact: Significantly reduced measles-associated pneumonia and mortality.
      • Recommendation: Universal vaccination for children.
    5. Pertussis (Whooping Cough) Vaccine (DTaP/Tdap):
      • Targets: Bordetella pertussis, which can cause severe pneumonia, especially in unvaccinated infants.
      • Impact: Reduces the incidence and severity of pertussis.
      • Recommendation: Universal vaccination for infants and booster doses for older children/adolescents. Tdap is also recommended for pregnant women to provide passive immunity to newborns.
    6. Respiratory Syncytial Virus (RSV) Immunization (Passive):
      • Targets: RSV, the leading cause of bronchiolitis and pneumonia in infants.
      • Palivizumab (Synagis): A monoclonal antibody given monthly during RSV season to high-risk infants (e.g., premature infants, those with chronic lung disease, significant congenital heart disease).
      • Newer options: Maternal RSV vaccine and longer-acting monoclonal antibodies are emerging.
      • Impact: Reduces the severity and hospitalization rates due to RSV in vulnerable infants.
    II. Improved Nutrition

    Malnutrition significantly impairs the immune system, making children more susceptible to infections, including pneumonia, and increasing the severity of illness.

    1. Exclusive Breastfeeding: For the first 6 months of life, breast milk provides essential antibodies and immune factors that protect infants from respiratory infections.
    2. Appropriate Complementary Feeding: After 6 months, introduce nutritious, age-appropriate complementary foods alongside continued breastfeeding up to 2 years and beyond.
    3. Adequate Overall Nutrition: Ensure children receive a balanced diet rich in vitamins and minerals to support a robust immune system. Addressing micronutrient deficiencies (e.g., Vitamin A, Zinc) can also be important.
    III. Environmental and Hygiene Measures

    Reducing exposure to pathogens and irritants is critical for preventing pneumonia.

    1. Improved Indoor Air Quality:
      • Reduce Exposure to Indoor Air Pollution: Promote the use of clean cooking fuels and improved cooking stoves to reduce exposure to biomass fuel smoke.
      • Avoid Tobacco Smoke Exposure: Strict avoidance of passive (secondhand) smoke exposure from parents/caregivers, as it irritates airways, impairs ciliary function, and increases susceptibility to respiratory infections.
    2. Good Hand Hygiene:
      • Frequent Handwashing: Educate children and caregivers on the importance of frequent and thorough handwashing with soap and water, especially after coughing/sneezing, before eating, and after using the toilet.
    3. Reduce Crowding: Minimizing overcrowding, especially in daycare settings or households, can reduce the transmission of respiratory pathogens.
    4. Clean Water and Sanitation: Access to clean water and adequate sanitation can indirectly prevent infections that weaken the immune system.
    IV. Health Promotion and Access to Care
    1. Early Recognition and Treatment of Illnesses: Promptly seek medical attention for respiratory symptoms to prevent progression to severe pneumonia.
    2. Management of Underlying Conditions: Effectively manage chronic conditions like asthma, cystic fibrosis, and congenital heart disease, which predispose children to pneumonia.
    3. HIV Prevention and Treatment: In regions with high HIV prevalence, preventing mother-to-child transmission and ensuring access to antiretroviral therapy for children with HIV are crucial, as HIV-positive children are at much higher risk of severe and recurrent pneumonia.
    4. Community Health Programs: Implement and support community-based health programs that promote child health, provide education, and improve access to primary healthcare services, especially in underserved areas.
    5. Antibiotic Stewardship: While a treatment strategy, responsible antibiotic use also plays a role in prevention by limiting the development of antibiotic-resistant bacteria, which could make future pneumonia harder to treat.

    Pneumonia in Children Read More »

    Want notes in PDF? Join our classes!!

    Send us a message on WhatsApp
    0726113908

    Scroll to Top
    Enable Notifications OK No thanks